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Abstract
Comprehensive Model of Lung Cancer Prediction and Prognosis
Joseph J. Putila
Two unresolved issues in the treatment of non-small cell lung cancer are the assessment of risk
of recurrence beyond the use of tumor stage alone, and the selection of an effective chemotherapeutic
agent for patients with similar tumor morphology. A prognostic model able to identify high or low-risk
patients with a high degree of accuracy can be used to inform clinicians on potential improvements to
the current clinical practice. Clinical presentation, pathology, demographics, and genomics have been
independently verified as influencing survival. A comprehensive model capable of incorporating
multiple predictors into a unified measure has the potential to simplify risk assessment and more
accurately model the determinants of patient outcome.
In order to accomplish this, patient characteristics including tumor stage, grade, patient race,
age, COPD status ,and sex were assessed using Cox proportional hazards modeling across combinations
of surgical, radiological, and chemotherapeutic treatments. A comprehensive model combining these
factors was created and showed superior prognostic ability when compared to stage alone. In order to
identify miRNA markers for chemoresponse, this patient data was then compared with information on
miRNA expression from both a clinical cohort and the NCI-60 anti-cancer screen. A set of predictive and
prognostic miRNA were selected by measuring the association between miRNA expression and diseasespecific patient survival. The sets of significant miRNA were seen to have strong associations with
mechanisms of apoptosis and cell-cycle control in an analysis of networked molecules.
The results show that a comprehensive model lends itself to a more accurate assessment of
patient risk, and that these improvements persist across a variety of patient profiles and treatment
modalities. Additionally, miRNA expression appears to play a role in patient response to chemotherapy
when assessed across categories of disease progression. Multiple miRNA showed significant
associations with disease-specific survival in the population analysis. These associations were able to be
corroborated in the clinical and cellular data, demonstrating that this approach may be useful for
identifying broad patterns of genomic expression which influence sensitivity and resistance to
chemotherapy, and hold promise in further developing clinical tools for prediction. It was shown that
the large, well-annotated, and diverse patient sample derived from registry and administrative data can
be leveraged to approach two of the major unresolved issues in the treatment of non-small cell lung
cancer.
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Chapter1:
Introduction
Lung cancer represents a significant burden on the health and well-being of the U.S. population,
and many other industrialized nations across the world. The low cure rate of lung cancer and the
pervasiveness of its main causal factor, smoking, act together to produce a disease which is both deadly
and widespread. While efforts to reduce the prevalence of smoking offer the most straightforward
preventative solution, treatment of lung cancer in a clinical setting will remain a key component of
managing the population disease burden for decades to come.
Lung and Bronchus cancer is currently the second most common cancer for both U.S. males and
females behind cancers of the prostate and breast, respectively, with nearly half as many cases
(American Cancer Society, 2012). Despite being less prevalent than other sites, lung cancer manages to
lead all other cancers in mortality for both men and women. Lung cancer is responsible for as many
deaths per year as cancers of the prostate, colon, and pancreas combined in men. In women, the
annual number of deaths from lung cancer is equal to the total for the next two deadliest cancers,
breast and colon. Because of this, improvements in lung cancer care represent an opportunity to
significantly reduce the burden of disease on the population level.
Two unresolved issues in the treatment of non-small cell lung cancer are the assessment of risk
of recurrence, and the selection of an effective chemotherapeutic agent for patients with similar tumor
morphology. Relapse is the major cause of treatment failure and a major cause of death even among
patients treated with surgical resection. Tumor stage alone has been unable to accurately select
patients who may benefit from additional treatment such as adjuvant chemotherapy. Because of this,
many early-stage patients experience recurrence even with surgical resection. Currently, 35–50% of
stage I NSCLC patients will relapse within five years (Hoffman et al., 2000; Naruke et al., 1989). Although
tumor stage is the strongest prognostic factor, other factors such as sex, age, race, comorbidities, and
tumor grade contribute to survival as well (Clegg et al., 2002; Visbal et al., 2004; Orourke et al., 1987;
Brown et al., 1996). We hypothesized that a prognostic model capable of combining multiple factors
which influence survival would be able to provide refined prognostication when compared to the use of
tumor stage alone.
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An advantage of a comprehensive model of survival is the ability to aid in the selection of an
appropriate therapy for each patient by providing an estimated measure of risk. The identification of
high-risk patients who stand to benefit from additional treatment, more aggressive treatment, or
enhanced follow-up is one of the key applications of a comprehensive prognostic model. Accurately
incorporating multiple factors which influence survival has utility in selecting patients who may benefit
from a modified treatment strategy as a result of increased or decreased risk relative to patients with
similar clinical profiles. Currently, there are no models for non-small cell lung cancer prognosis in
widespread clinical use which are able to incorporate multiple prognostic factors, but similar tools have
been successful for breast cancers (Ravdin et al., 2001). Similar approaches to combining prognostic
factors have shown promise in improving prognostication in lung cancer, but are restricted to limited
treatment groups such as chemoradiation (Dehing-Oberije et al., 2008; Dehing-Oberije et al., 2009).
In order to evaluate the comprehensive prognostic model, individual factors were thoroughly
assessed both as independent predictors in their ability to stratify patients into high and low-risk groups
in a Kaplan-Meier analysis, and as coefficients in independent and controlled Cox regressions. The
presented approach ensures that the model is able to function in a robust manner across a wide range
of patient characteristics in order to increase its usefulness and generalizability to other patient
populations. Although there is no standardized approach for building or evaluating prognostic models,
the method of bootstrap estimation and internal validation on Harrell’s C, Nagelkerke’s R2, ROC, and
Brier score provide a robust analytical framework in-line with established theory (Schumacher et al.,
2003; Steyerberg et al., 2001). These estimates, as well as the assessment of factors in univariate Cox
models and on patient stratification, give a reasonable assessment of the utility of additional factors in
improving prognostication.
The second unresolved issue, treatment prediction, is another area where of the selction of
biomarkers associated with patient survival can benefit clinical decision-making. This is particularly true
for response to chemotherapy, as the response to a given therapeutic agent can vary greatly between
patients with seemingly similar clinical profiles and tumor morphology. Because of this, there is much to
be gained by selecting patients who may benefit from the administration of chemotherapy and the
selection of a specific agent with a higher probability of being effective. Avoiding the use of
chemotherapy in patients highly unlikely to benefit from its administration also reduces the chance of
unwanted side-effects or complications while ensuring that healthcare budgets are used in the manner
which is most beneficial for a given population.
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MiRNA biomarkers have the ability to enhance treatment selection in patients with similar
tumor morphology. The use of miRNA has several advantages over other available biomarkers. It has
been shown that miRNA are more stable in prepared tissue relative to mRNA (Jung et al., 2010; Mraz et
al., 2009). This increased stability offers a significant advantage when attempting to measure expression
in existing patient samples, most notably those prepared using formalin fixation (Xi et al., 2007). In
addition, miRNA can be found in circulating plasma (Chen et al., 2012; Mitchell et al., 2008). The ability
to collect miRNA non-invasivlely is a sizable advantage in the practical application of diagnostic and
predictive tests over other biomarkers which may require biopsy or resected tissue. The inherent
regulatory effect of miRNA on post-transcriptional regulation and signalling also represents an
oppurtunity to focus on broad patterns of epigenetic regulation which are less well-represented with
other markers (Iorio & Croce, 2012; Avraham & Yarden, 2012). This advantage is highlighted by the
networks of regulatory targets and associated molecules generated from the sets of significant miRNA.
Multiple aspects of chemoresponse such as the control of apoptosis and the cell-cycle show a high
degree of interconnectivity with the predictive miRNA set and their associated molecules.
Numerous studies have shown that mRNA biomarkers can be used for predicting survival in
lung cancer patients (Wan et al., 2012; Raponi et al., 2006; Chen et al., 2007; Beer et al., 2002). Similar
studies have shown that miRNA can also be used in the diagnosis and prognosis of lung cancer (Wang et
al., 2009; Rabinowits et al., 2009; Yu et al., 2008; Markou et al., 2008; Fabbri et al., 2007; Raponi et al.,
2009). The development of a biomarker model of chemoreponse has the potential to both enhance
response rates seen in patients treated with chemotherapy and to highlight the potential regulatory
networks which influence patient survival and mediate chemoresponse. The main limitations of clinical
studies are small sample size and non-random treatment assignment. Because the sample sizes are
small and patient survival is influenced by variable treatment assignment it is difficult to assess the role
of miRNA within treatment sub-groups.
An approach is presented for the use of registry data in the valdiation of miRNA markers found
to be significant in a clinical population, and as a source of additional markers. This approach aims to
circumvent the common issue of inadequate sample size imparted by cost and recruitment barriers. It
was hypothesized that by linking miRNA expression in tumor samples to information on patient
treatment and follow-up by measures of tumor progression, it would be possible to examine the role of
miRNA in influencing survival and chemoresponse given a variety of treatment approaches. Using a
clinical cohort (Raponi et al., 2009), an initial set of prognostic miRNA were selected by assessing the
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association between expression and survival using Cox modeling and Kaplan-Meier stratification. These
miRNA were then validated in the population cohort by estimating a linear regression between average
miRNA expression and average survival for each unique combination of tumor T,N,M, and grade.
Predictive miRNA were selected through the use of linear regression and validated using Cox modeling
and Kaplan-Meier stratification in groups of patients having received a specific agent. In each case,
miRNA expression was assessed using multiple measures of association in order maximize the utility of
the set as classifiers (Pepe et al., 2004).
The significant predictive miRNA were then validated using data from cell-line experiments
quantifying chemoresponse relative to miRNA expression. The use of cell-lines provides an avenue for
simulating ex-vivo analyses seen to be useful in validating markers of chemoresponse in lung and other
cancers (Vogt et al., 2002; Gallion et al., 2006; Chen et al., 2011; Coleman et al., 2004). Finally, Ingenuity
Pathways Analysis was used to generate functional networks in which the set of significant miRNA and
associated molecules were over-represented. These networks centered around functional aspects of
cell proliferation and death, and provided insight into some of the potential regulatory networks
through which miRNA may influence chemoresponse.
This document is divided into five chapters, each representing a component of a theoretical
framework for developing a comprehensive population-based model of prognosis and prediction for
non-small cell lung cancer. Chapter 2 outlines the issue of combining multiple prognostic factors to
improve prognostic ability over a model using only tumor stage. Chapter 3 extends the analytical
framework established in Chapter 2 by including data on chemotherapy and co-morbid conditions.
These data were derived from administrative records, and allow for the assessment of the contribution
of COPD to the prognostic ability of the comprehensive model and assessment of the accuracy of
predictions in patients treated with chemotherapy. Having demonstrated a method for using
demographic and clinical information to improve prognostication, Chapter 4 explores the role of miRNA
in mediating chemoresponse. As with the previous chapters, the large and diverse population sample is
leveraged to select sets of prognostic and predictive miRNA biomarkers. The final chapter, Chapter 5,
concludes by highlighting the advantages of the analytical frameworks used and areas for further
refinement.
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Chapter2:
Combining Clinical, Pathological, and Demographic Factors
Refines Personalized Prognosis of Lung Cancer: A Populationbased Study
Published in PLoS One
Putila J, Remick SC, Guo NL, 2011 Combining Clinical, Pathological, and Demographic Factors Refines
Prognosis of Lung Cancer: A Population-Based Study. PLoS ONE 6(2): e17493.
doi:10.1371/journal.pone.0017493

Abstract
Background: In the treatment of lung cancer, an accurate estimation of patient clinical outcome is
essential for choosing an appropriate course of therapy. It is important to develop a prognostic model
by combining clinical, pathological and demographic factors for individualized clinical decision making.
Methodology: A total of 234,412 patients diagnosed with adenocarcinomas or squamous cell
carcinomas of the lung or bronchus between 1988 and 2006 were retrieved from the SEER database to
construct a prognostic model. SEER patients were randomly assigned to a training or test set. Two
additional patient cohorts (n = 1,991) from multiple hospitals were also used as test sets. A patient
stratification scheme was developed on the training set using a Cox proportional hazard model with
tumor stage, tumor grade, patient age, gender, and race included in the model. The training model was
used to predict the clinical outcome for each patient in the test sets.
Principal Findings: The comprehensive model consistently outperformed the model using stage alone on
Harrell’s C, Nagelkerke’s R2, and Brier Scores. The comprehensive model also performed better than
stage alone when splitting the SEER patients into four treatment modalities. Two additional patient
cohorts (n = 1,991) were also used as external validation, with the comprehensive model again
outperforming the model using stage alone on the three metrics used.
Conclusion: These results demonstrate the feasibility of constructing a precise prognostic model
combining multiple clinical, pathologic, and demographic factors. The comprehensive model significantly
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improves individualized prognosis upon AJCC tumor staging and is robust across a range of treatment
modalities, the spectrum of patient risk, and in novel patient cohorts.

Introduction
Lung cancer is one of the most aggressive cancer types and consistently the leading cause of
cancer-related death in the United States for both men and women. There are around 215,000 new
cases and 161,000 deaths annually (Jemal et al., 2008). Non-small cell lung cancer (NSCLC) accounts for
about 80% of lung cancer cases. Although tumor stage is strongly predictive of survival in most cases, it
does not explain the distinct variability in treatment outcome within patients of the same stage.
Currently, surgery is the major treatment option for patients with stage I NSCLC. However, 35–50% of
stage I NSCLC patients will relapse within five years (Hoffman et al., 2000; Naruke et al., 1989), which is
the major cause of treatment failure, i.e. death from lung cancer. It remains an unsolved challenge for
physicians to reliably identify patients at high risk for tumor recurrence as candidates for adjuvant
chemotherapy.
Prognostic factors such as age, gender, and tumor grade, have been shown to be strongly
associated with survival. Age is an established risk factor for the development of lung cancer and can
also influence the type of treatment received either due to medical coverage or the existence of comorbid conditions which preclude certain therapies (Brown et al., 1996; Orourke et al., 1987). Males
diagnosed with lung cancer consistently experience poorer survival than do females (Visbal et al., 2004).
This gender difference persisted even when controlling for other variables such as tumor stage, age at
diagnosis, and treatment.
Race has also been shown to be a significant predictor of survival, with Asians and Pacific
Islanders experiencing better survival in both prospective (Thatcher et al., 2005) and population-based
studies (Clegg et al., 2002). While the disease mechanism and genetic background is not well
characterized, the consistency of this finding is useful in terms of prognostication and treatment.
The emerging use of genetic markers may enable physicians to make treatment decisions based
on the specific characteristics of individual patients and their tumors, instead of population statistics
(Dalton & Friend, 2006). This study presents an alternative avenue to improve personalized prognosis of
NSCLC by combining clinical, pathological, and demographic factors in a population-based study (n =
234,412). This comprehensive model was tested across a number of treatment modalities and blindly
validated on multiple separate patient cohorts (n = 1,991). The comprehensive model achieved a
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significant improvement in prognostication when compare with AJCC tumor staging system including
cases converted to AJCC 7th Edition (American Joint Committee on Cancer, 2010). This patient
stratification scheme could be integrated with future clinically-validated prognostic gene signatures for
personalized prognosis of NSCLC.

Materials and Methods
Acquisition of Patient Cohorts
A cohort of patients diagnosed with lung cancer was retrieved from the Surveillance
Epidemiology and End Results (SEER) database (SEER, 2010). The SEER database is an aggregate of
registry data from specific geographic areas covering approximately 26 percent of the U.S. population,
and contains clinical, demographic, treatment, and follow-up information for a variety of cancers. The
requirements for inclusion in the study included a diagnosis of primary lung adenocarcinoma (ICD-O-3
8140 to 8380) or squamous cell carcinoma (ICD-O-3 8050 to 8080) between the years 1988 and 2006, as
well as available data on tumor stage, tumor grade, race, age, gender, disease-specific survival, and
treatment. Patients who were diagnosed via autopsy or death certificate, or had no valid survival data
were excluded from the analysis. A total of 234,412 patients met the inclusion criteria. Patients staged
using the 6th edition of AJCC staging, in general 2004 and newer diagnoses, were recoded to the 7th
edition based on the proposed staging changes in the AJCC Staging Manual (American Joint Committee
on Cancer, 2010) and information about tumor size, extension, metastasis, and lymph node involvement
found in the SEER database where possible. A total of 58,634 cases were able to be converted from the
6th to the 7th edition.
Two additional patient cohorts were also used as validation sets. De-identified data for a total of
1,552 patients treated at the Mary Babb Randolph Cancer Center at West Virginia University from 1990
to 2009 with squamous cell carcinoma (n = 758) or adenocarcinoma (n = 794) were obtained. The study
was approved with an IRB exemption from West Virginia University. According to HIPAA regulation, deidentified clinical information can be used in research without prior consent from the patients. A total of
439 lung adenocarcinoma cases were also obtained from Shedden et al (Shedden et al., 2008) for
patients with Stage I-IIIB cancers. These patients were treated in H. Lee Moffitt Cancer Center,
University of Michigan Comprehensive Cancer Center, Dana-Farber Cancer Institute, and Memorial
Sloan-Kettering Cancer Center. Patients have provided consent. These data have been published in
Shedden et al (Shedden et al., 2008) before. It is not clear if patients have provided written or verbal
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consent. The protocols were approved with Institutional Review Boards (IRB-Med) of the respective
institutes. The total numbers and distribution of patient characteristics are described in detail in Tables
2.1 and 2.2.

Table 2.1. Outline of patient clinical characteristics for major histology of non-small cell lung cancer and AJCC
staging editions retrieved from SEER database.

Adenocarcinoma
Squamous
Variable
AJCC 3rd+6th
AJCC 7th
AJCC 3rd+6th
AJCC 7th
Age
Mean Age (σ)
66.9 (11.4)
67.0 (11.3)
69.0 (9.9)
69.8 (10.2)
Sex
Male (%)
75,753 (50.4)
18,550 (48.3)
55,794 (66.2)
12,678 (62.7)
Race
API
10,377 (6.9)
2,853 (7.4)
3,877 (4.6)
885 (4.4)
Black
14,432 (9.6)
3,620 (9.4)
10,373 (12.3)
2,317 (11.5)
White
125,349 (83.5)
31,953 (83.2)
70,004 (83.1)
17,006 (84.2)
Tumor Stage*
I
36,052 (24)
8,295 (21.6)
21,495 (25.5)
4,090 (20.2)
II
6,118 (4.1)
4,661 (12.1)
4,899 (5.8)
3,026 (15)
IIIA
11,447 (7.6)
5,773 (15)
11,284 (13.4)
4,497 (22.2)
IIIB
26,905 (17.9)
3,008 (7.8)
19,933 (23.7)
2,435 (12)
IV
69,636 (46.4)
16,690 (43.4)
26,643 (31.6)
6,160 (30.5)
Tumor Grade
Grade 1
11,415 (7.6)
3,602 (9.4)
2,559 (3.0)
464 (2.3)
Grade 2
28,999 (19.3)
8,637 (22.4)
22,877 (27.2)
5,700 (28.2)
Grade 3
45,424 (30.3)
9,796 (25.5)
32,380 (38.4)
7,266 (36)
Grade 4
64,320 (42.8)
16,391 (42.7)
26,438 (31.4)
6,779 (33.5)
*Sub-stages for stage I and II patients are combined as it was not possible to differentiate between substages for all patients diagnosed with AJCC 3rd and 6th staging systems. Categorical variables show the N
and percentage of the total for each category. Age is represented as the mean age with the standard
deviation in parentheses.
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Table 2.2. Outline of patient clinical characteristics for external non-small cell lung cancer validation sets.

Variable
Age
Mean Age (σ)
Sex
Male
Race
API
Black
White
Tumor Stage
I
II
IIIA
IIIB
IV
Tumor Grade
Grade 1
Grade 2
Grade 3
Grade 4

Adenocarcinoma
Director’s Challenge
MBRCC
(Shedden et al., 2008)

Squamous
MBRCC

64.4 (10.1)

64.3 (11.3)

67.1 (10.1)

218 (50.3%)

419 (52.8)

479 (63.2)

7 (1.6)
12 (2.7)
420 (95.7)

2 (0.3)
9 (1.1)
783 (98.6)

1 (0.1)
15 (2.0)
742 (97.9)

276 (62.9)
95 (21.6)
57 (13)
11 (2.5)
0 (0)

181 (22.8)
48 (6)
74 (9.3)
95 (12)
396 (49.9)

176 (23.2)
57 (7.5)
111 (14.6)
115 (15.2)
299 (39.4)

60 (13.7)
208 (47.4)
166 (37.8)
5 (1.1)

62 (7.8)
137 (17.2)
231 (29)
364 (45.8)

22 (2.9)
172 (22.6)
267 (35.2)
297 (39.2)

Conversion of Cases to AJCC 7th Edition
Cases diagnosed from 2004 onward were able to be converted into the AJCC 7th Edition. The
original TNM staging information regarding tumor size and extension (T), lymph node status (N), and
distant metastasis (M) was retrieved from the SEER data. Using this information, the T, N, and M
classifiers were recoded according to the new guidelines (American Joint Committee on Cancer, 2010)
and then used to determine the AJCC 7th stage.
Model Construction and Statistical Analyses
Disease-specific survival was analyzed primarily using a Cox proportional hazards model. This
model estimates the effect of a set of factors on the time until an event, in this case death, following a
diagnosis. Four models, one for each of the histology and AJCC staging combinations, were estimated.
A total of 500 bootstrapped samples equal in size to the original adenocarcinoma and squamous cell
carcinoma patient cohorts were constructed. This method has been seen to be superior to split-sample
techniques (Steyerberg et al., 2001), and in general produces less biased estimates with a smaller
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variance. A Cox model was then fit on each bootstrapped sample. In order to determine the advantage
of using other variables in addition to AJCC stage, two sets of variables were used. The first contained
information on tumor stage and grade, patient age, race, and gender. The second contained only
information on tumor stage and used as a model of current clinical practice. The final model used the
mean value of all coefficients generated from the bootstrapped samples, as the distribution of hazard
scores was normal. Hazard scores were calculated for each patient in the original samples based on the
final model constructed from the means. The formula used to specify the model is shown below,
demonstrating the relationship between hazard h for patient i at time t and the coefficients, β, for
variables 1 through k with values of x.

l

o
hi (t ) = gα (t ) + β 1 xi1 + β 2 xi 2 +  + β kxi

Patients still alive or dead due to unrelated causes were censored at the time of last follow-up
or death, respectively. Internal performance was measured using Harrell’s C, Nagelkerke’s R2, and Brier
Scores. Harrell’s C is a measure of concordance which is representative of the area under an ROC curve
ranging between 0 and 1, with higher scores indicating greater concordance (Steyerberg et al., 2001).
Nagelkerke’s R2 is functionally similar to the R2 value in linear models, ranging between 0 and 1 with
higher values explaining more variance, with this variant being calculated on the log-likelihood scale.
The Brier score represents the average prediction error, ranging from 1 to 0, with lower values indicating
a lower average error. The model constructed using the training set was then further validated on SEER
sub-cohorts as well as patients from the MBRCC and the Director’s Challenge (Shedden et al., 2008)
cohorts, without re-estimating parameters of the model. Selection of patient stratification cutoffs was
done by iterating through a range of possible cutoff values and measuring the difference in survival
between High, Intermediate, and Low risk groups defined according to the Full and Stage Only models at
each cutoff. The set of cutoff values that offered the greatest improvement in prognostication over the
Stage Only model was selected for use in the final model. Statistical analyses were conducted with the
pamr, pec, Design, and survival packages in R v2.11.0.

Results
This study focused on two major cell types of NSCLC, lung adenocarcinoma and squamous cell
lung cancer. For each cell type, a comprehensive model was constructed to include the previous AJCC
staging system (the 3rd and 6th editions) and the current AJCC 7th edition. The clinical characteristics of
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the SEER patient population are listed in Table 2.1, and two external validation cohorts are summarized
in Table 2.2.
The models were constructed by taking the mean of each coefficient from a Cox model fit on
500 bootstrapped samples of each original cohort. This resulted in a total of four models, one for each
of the two AJCC staging systems and two cell types considered in combination with one another. These
models were tested on the original samples in their entirety, sub-cohorts representative of four major
treatment modalities, and two external cohorts.
In the overall studied patient population, earlier stage at diagnosis was significantly related to
disease-specific survival in a univariate Cox Proportional Hazards model in both adenocarcinoma and
squamous cell carcinoma for each AJCC Staging system (P<0.05). In the multivariate analyses AJCC
stage, tumor grade, patient age, race, and gender were all significant. Specifically, lower tumor grade,
younger age at diagnosis, and being of Asian/Pacific Islander descent were all significantly associated
with improved survival (P<0.05). Being male or having a later stage at diagnosis was associated with a
poorer outcome across all groups. The comprehensive model incorporating all these factors showed
significantly improved prognostic categorization when compared with the AJCC staging system, including
the latest edition. The improvement across all patients for each staging system and histology is
demonstrated in Figure 2.1.
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Figure 2.1. Prediction of survival at 60 months for the AJCC 3rd and 6th Editions (top) and 30 months for the
cases converted to the AJCC 7th Edition (bottom) for both lung adenocarcinoma (left) and squamous cell lung
cancer (right) using ROC curves. P<0.05 indicates that the full model is significantly more accurate in predicting
disease-specific survival than tumor stage.

The patients were then assigned into one of four treatment categories based on the treatment
record in SEER database. These categories were surgery alone, radiation alone, surgery with radiation,
and no treatment listed. For simplicity, this determination was based on the presence or absence of any
surgical or radiation procedure, regardless of the specific procedure.
Patient stratification for lung adenocarcinoma (the AJCC 3rd and 6th edition)
A total of 150,158 lung adenocarcinoma patients staged with the 3rd and 6th AJCC Editions met
the criteria for inclusion. Harrell’s c statistic was calculated for both the model using stage alone and
the comprehensive model using additional variables. The comprehensive model had a higher C statistic
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(0.732) compared to the stage only model (0.694). A similar improvement was seen for Nagelkerke’s R2
(0.294 v. 0.253) and Brier score (0.134 v. 0.143). The distribution of Hazard scores and general trend in
improvement is shown in Figure 2.2 for all patients, and for patients treated with surgery alone.
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Figure 2.2. Results of survival analysis on lung adenocarcinoma patients staged using AJCC 3rd or 6th Edition. a)
Histogram of Hazard Scores obtained from the comprehensive model. b) Probability of death from lung cancer
prior to 24 months based on Hazard Scores calculated using the comprehensive model. c) Kaplan-Meier survival
plots for low-, intermediate-, and high-risk groups determined by the comprehensive model (blue) and AJCC
staging alone (orange). d) Average survival of each group in months, with log-rank P-values shown. L: low-risk;
Int: intermediate-risk; H: high-risk defined by the full model. Stage only model contains patient with stage 1, 2,
3a, 3b and 4. e) Kaplan-Meier survival plots for each risk group in patients who received surgery without
radiation. f) Average survival for risk groups in patients who received surgery without radiation. L: low-risk; Int:
intermediate-risk; H: high-risk. Stage only model contains patient with stage 1, 2, 3a, 3b and 4.

15
The analysis comparing the performance of each model on treatment subgroups also showed a
similar improvement in predictive ability with the comprehensive model. In patients who received
surgery alone, the comprehensive model had consistently better estimates for Harrell’s C (0.768 v
0.723), Nagelkerke’s R2 (0.225 v 0.173) and Brier Score (0.206 v. 0.210). A similar improvement,
summarized in Tables 2.3, 2.4 and 2.5, was observed in patients receiving radiation alone, surgery with
radiation, and those with no treatment listed.
Lung adenocarcinoma cases converted to the AJCC 7th edition
A total of 38,426 lung adenocarcinoma cases were converted into the AJCC 7th edition. It is
important to note that the converted cases represent a much smaller cohort and have shorter follow-up
time compared to the AJCC 3rd and 6th Edition cohorts. When considering the entire patient sample,
Harrell’s C for the comprehensive v. the stage only model (0.763 v. 0.731), Nagelkerke’s R2 (0.305 v.
0.274) and Brier score (0.144 v 0.150) were all improved. These effects persisted in when considering
the four patient sub-cohorts defined by treatment modality, although the performance of both models
was similarly decreased when compared to the original staging system. The patient sub-cohort with no
treatment listed performed the worst on all three metrics. Figure 2.3 shows the distribution of Hazard
scores and improvement over the use of stage alone when constructing risk groups.
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Figure 2.3. Results of survival analysis on lung adenocarcinoma patients converted to AJCC 7th Edition. a)
Histogram of Hazard Scores obtained from the comprehensive model. b) Probability of death from lung cancer
prior to 24 months based on Hazard Scores calculated using the comprehensive model. c) Kaplan-Meier survival
plots for low-, intermediate-, and high-risk groups determined by the comprehensive model (blue) and AJCC
staging alone (orange). d) Average survival of each group in months, with log-rank P-values shown. e) KaplanMeier survival plots for each risk group in patients who received surgery without radiation. f) Average survival
for risk groups in patients who received surgery without radiation. L: low-risk; Int: intermediate-risk; H: high-risk
defined by the full model. Stage only model contains patient with stage 1, 2, 3a, 3b and 4.
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Prognostication of squamous cell lung cancer (the AJCC 3rd and 6th edition)
A total of 84,254 squamous cell lung cancer patients diagnosed with the ACC 3rd and 6th staging
system met the inclusion criteria. Performance of both the comprehensive and stage only model were
slightly decreased when compared to the adenocarcinoma patients in the overall patient sample.
However, there was still an improvement in the overall treatment cohort when using the comprehensive
model on Harrell’s C (0.722 v. 0.706), Nagelkerke’s R2 (0.289 v. 0.274), but not on Brier score (0.119 v
0.119). There was a similar improvement in the sub-cohorts defined by treatment modality, with the
comprehensive model performing as well or better than the stage only model in all sub-cohorts. Figure
2.4 shows the improvement in patients receiving any treatment, and those receiving surgery alone when
constructing risk groups, as well as the distribution of Hazard scores.
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Figure 2.4. Results of survival analysis on squamous cell lung cancer patients staged using AJCC 3rd or 6th
Edition. a) Histogram of Hazard Scores obtained from the comprehensive model. b) Probability of death from
lung cancer prior to 24 months based on Hazard Scores calculated using the comprehensive model. c) KaplanMeier survival plots for low-, intermediate-, and high-risk groups determined by the comprehensive model
(blue) and AJCC staging alone (orange). d) Average survival of each group in months, with log-rank P-values
shown. e) Kaplan-Meier survival plots for each risk group in patients having received surgery without radiation.
f.) Average survival for risk groups in patients who received surgery without radiation. L: low-risk; Int:
intermediate-risk; H: high-risk defined by the full model. Stage only model contains patient with stage 1, 2, 3a,
3b and 4.
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Squamous cell lung cancer cases converted to the AJCC 7th edition
A total of 20,208 squamous cell lung cancer cases could be converted to the AJCC 7th edition.
Prediction was similar or improved when using the comprehensive model on all three metrics and in all
treatment cohorts considered, however the difference between the two models was marginal in a few
cases. The most marked improvement in prediction was in the sub-cohort of patients receiving surgery
only. For that group, the comprehensive model outperformed the stage only model on Harrell’s C
(0.689 v. 0.670), Nagelkerke’s R2 (0.064 v. 0.055), and marginally on Brier score (0.113 v. 0.114). Figure
2.5 shows the improvement in risk group construction over the model using stage alone, as well as the
distribution of Hazard scores.
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Figure 2.5. Results of survival analysis on squamous cell lung cancer patients converted to AJCC 7th Edition. a)
Histogram of Hazard Scores obtained from the comprehensive model. b) Probability of death from lung cancer
prior to 24 months based on Hazard Scores calculated using the comprehensive model. c) Kaplan-Meier survival
plots for low-, intermediate-, and high-risk groups determined by the comprehensive model (blue) and AJCC
staging alone (orange). d.) Average survival of each group in months, with log-rank P-values shown. e) KaplanMeier survival plots for each risk group in patients who received surgery without radiation. f.) Average survival
for risk groups in patients who received surgery without radiation. L: low-risk; Int: intermediate-risk; H: high-risk
defined by the full model. Stage only model contains patient with stage 1, 2, 3a, 3b and 4.

21
Treatment selection for stage I surgical patients
Patients with stage I cancers who were treated with surgery alone were extracted for further
analysis to determine whether the comprehensive model could identify patients who may benefit from
a more aggressive therapy. In most cases, stage I patients that received surgery had the most favorable
outcome compared to other stages or treatment modalities, meaning that this cohort represents an
extreme tail of the patient risk spectrum.
The models developed on the overall patient samples were applied to stage I patients that had
received surgery alone in order to determine the predictive ability of the comprehensive and stage only
models in a cohort with a more favorable outcome. For adenocarcinoma patients staged using AJCC 7th
Edition (N=6,872), the comprehensive model performed better on Nagelkerke’s R2 (0.021 v. 0.002) and
Brier score (0.0541 v. 0.0552) but did not outperform the stage only model on Harrell’s C (0.371
v.0.469). However, when using the median hazard score to split patients into low and high-risk groups,
the comprehensive model was able to select a group of low-risk patients with better survival (16.53 v.
16.15 months, P=0.0008). The comprehensive model performed similarly to the stage only model in
squamous cell patients (N=2,953), with no significant difference between the risk groups defined by
each model (P>0.05). The comprehensive model was also able to further separate stage IA and stage IB
patient groups into high and low-risk groups with significantly different survival curves (p<0.05) for both
adenocarcinoma and squamous cell carcinoma, as shown in Figures 2.6 and 2.7, respectively.
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Figure 2.6. Results of survival analysis on lung adenocarcinoma patients diagnosed with stage IA or IB disease.
The Kaplan-Meier plots show the difference between low- and high-risk groups as determined by the
comprehensive model. Data on sub-stage was only available for patients staged using the AJCC 6th Edition
staging system (2004 and later) and for those patients converted into the 7th Edition.
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Figure 2.7. Results of survival analysis on squamous cell lung carcinoma patients diagnosed with Stage IA or IB
disease. The Kaplan-Meier plots show the difference between low- and high-risk groups as determined by the
comprehensive model. Data on sub-stage was only available for patients staged using the AJCC 6th Edition
staging system (2004 and later) and for those patients converted into the 7th Edition.

External Validation
The comprehensive model was also able to improve prognostication in the external validation
sets from MBRCC and Shedden et al (Shedden et al., 2008). Patients with both adenocarcinomas
(n=794) and squamous cell carcinomas (n=758) were available from the MBRCC cohort, with only
adenocarcinoma patients (n=439) available from the Director’s Challenge cohort (Shedden et al., 2008).
The comprehensive model performed consistently better across all three metrics considered when the
models estimated using the SEER cohort was applied to the cohorts from MBRCC and the Director’s
Challenge study, with the results being consistent across histology in the MBRCC cohort. The model
appeared to perform much better in the MBRCC cohort, possibly due to the lack of stage IV patients in
the Director’s Challenge cohort. These results are summarized in Tables 2.3, 2.4, and 2.5. Improvement
in the construction of risk groups when using the comprehensive model is shown in Figure 2.8
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Table 2.3. Harrell’s C-statistics from each model for each of the patient cohorts, separated into AJCC coding
system, treatment modality, and histology where possible.

All SEER Patients
Surgery Only
Radiation Only
Both Surg+Rad
No Treatment
MBRCC
Dir's Challenge

Adenocarcinoma
AJCC 3+6
FM
SO
0.732
0.694
0.768
0.723
0.631
0.608
0.688
0.677
0.601
0.542
0.721
0.708
0.687
0.660

AJCC 7
FM
0.763
0.742
0.665
0.696
0.607
N/A
N/A

SO
0.731
0.707
0.632
0.678
0.558
N/A
N/A

Squamous Cell Carcinoma
AJCC 3+6
AJCC 7
FM
SO
FM
0.722
0.706
0.733
0.762
0.742
0.689
0.647
0.636
0.666
0.688
0.674
0.682
0.582
0.567
0.598
0.695
0.681
N/A
N/A
N/A
N/A

SO
0.717
0.670
0.658
0.663
0.580
N/A
N/A
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Table 2.4. Nagelkerke’s R values from each model for each of the patient cohorts, separated into AJCC coding
system, treatment modality, and histology where possible.

All SEER Patients
Surgery Only
Radiation Only
Both Surg+Rad
No Treatment
MBRCC
Dir's Challenge

Adenocarcinoma
AJCC 3+6
AJCC 7
FM
SO
FM
SO
0.294
0.253
0.305
0.274
0.225
0.173
0.094
0.073
0.107
0.084
0.140
0.115
0.204
0.178
0.084
0.072
0.066
0.034
0.075
0.044
0.343
0.311
N/A
N/A
0.189
0.162
N/A
N/A

Squamous Cell Carcinoma
AJCC 3+6
AJCC 7
FM
SO
FM
SO
0.289
0.274
0.246
0.230
0.283
0.268
0.064
0.055
0.109
0.103
0.120
0.118
0.201
0.184
0.095
0.089
0.051
0.042
0.065
0.054
0.244
0.233
N/A
N/A
N/A
N/A
N/A
N/A

Table 2.5. Brier Scores from each model for each of the patient cohorts, separated into AJCC coding system,
treatment modality, and histology where possible.

All SEER Patients
Surgery Only
Radiation Only
Both Surg+Rad
No Treatment
MBRCC
Dir's Challenge

Adenocarcinoma
AJCC 3+6
AJCC 7
FM
SO
FM
SO
0.134
0.143
0.144
0.150
0.206
0.210
0.089
0.092
0.097
0.099
0.163
0.168
0.096
0.097
0.153
0.154
0.098
0.101
0.167
0.178
0.071
0.074
N/A
N/A
0.163
0.170
N/A
N/A

Squamous Cell Carcinoma
AJCC 3+6
AJCC 7
FM
SO
FM
SO
0.119
0.119
0.162
0.161
0.186
0.188
0.113
0.114
0.102
0.102
0.170
0.172
0.098
0.099
0.160
0.163
0.078
0.081
0.151
0.152
0.079
0.081
N/A
N/A
N/A
N/A
N/A
N/A
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Figure 2.8. Results of survival analyses performed on patient cohorts from the Director's Challenge Study and
the Mary Babb Randolph Cancer Center at West Virginia University.
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Discussion
Substantial efforts have been made to establish prognostic factors for patients with lung cancer
during the last two decades. The traditional prognostic factors are tumor size, vascular invasion, poor
differentiation, high tumor-proliferative index, and genetic alterations, including K-ras (Rodenhuis et al.,
1987; Slebos et al., 1990) and p53 (Horio et al., 1993). With the development of molecular
biotechnology, especially high-throughput microarrays, there have been a number of promising studies
on lung cancer prognosis by transcriptional profiling (Beer et al., 2002; Bhattacharjee et al., 2001; Bild et
al., 2006; Borczuk et al., 2005; Chen et al., 2007; Raponi et al., 2006; Shedden et al., 2008; Guo et al.,
2006; Guo et al., 2008). Although the traditional prognostic factors lack the information about the
biological diversity of lung cancer and have not reflected the complexity of molecular mechanisms of
these diseases, they are still the most valuable criteria for clinicians to decide the relevant therapies
(Ludwig & Weinstein, 2005). For instance, Adjuvant! (www.adjuvantonline.com) is a prognostic system
for lung cancer, breast cancer, and colon cancer based on traditional pathological features, including
age, tumor stage, and grade. It has been independently validated as a reliable aid to clinical decisionmaking on average breast cancer patients (Olivotto et al., 2005). A study by Birim and others (Birim et
al., 2006) also demonstrated that clinical factors outside of stage such as respiratory function,
comorbidity, and smoking behaviors could be used to refine prognosis in a smaller cohort (N=766) of
NSCLC patients.
In this study, we sought to investigate the impact of clinical, pathological, and demographic on
lung cancer survival using a population-based approach. It was found that the addition of pathological
and demographic variables to AJCC staging was able to significantly improve predictive ability in both
lung adenocarcinomas and squamous cell carcinomas. These additional variables accounted for
previously unexplained variation within and independent of stage, and resulted in a more accurate
assessment of the risk for tumor recurrence when evaluated as integrated prognostic indicators. This
effect persisted within multiple treatment modalities.
The comprehensive model was also able to improve prediction in stage I surgical
adenocarcinoma patients, with the low-risk group selected by the comprehensive model having
significantly better survival than the same group chosen using stage alone (P=0.0008). These patients
may not benefit from additional therapies while, conversely, those who failed to be selected as low-risk
may benefit from adjuvant chemotherapy.
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These results demonstrate that the comprehensive prognostic model was able to reliably
identify stage I NSCLC patients at higher risk for tumor recurrence, possibly benefitting from adjuvant
chemotherapy. The external validation results indicate that the comprehensive prognostic model
constructed from SEER population data could improve prognosis in multiple local hospitals.
The improvement seen is likely an underestimate, as the coefficients for stage only model, while
intended to be representative of current clinical practice, were estimated with the same rigor as the
comprehensive model likely resulting in a far more refined estimate of survival than could be garnered
from clinical experience. Furthermore, there was a similar improvement in prediction when cases were
converted into the AJCC 7th staging edition despite smaller sample sizes and shorter follow-up, indicating
that the improvement attributed to the additional variables is not merely an artifact of shortcomings in
the AJCC staging system which were addressed in the previous round of revisions. These findings show
promise for a clinical model capable of considering these impactful factors in a robust and intuitive
manner.
A limitation of the study is that it assumes that the quality or effectiveness of the treatment
patients receive is similar across the study sample. As the patients come from a large number of
different institutions it is unlikely that the assumption holds true. A separate analysis utilizing median
county income as a surrogate measure for socio-economic status showed that there was a significant
positive association between median county income and survival independent of other clinical,
demographic, or pathologic factors. However, this sort of measure is not appropriate for individual
prediction and was omitted from the model.
This study demonstrated the feasibility of refining NSCLC prognosis using easily collectable
patient information in a large retrospective population study. A significant limitation of the study was
the lack of information on the use of chemotherapy and co-morbidities present at the time of diagnosis.
It is expected that inclusion of data found in the linked SEER-Medicare database will more appropriately
address these issues and allow for further refinement of the model. In future research, we plan to
construct a comprehensive model to estimate treatment benefits of commonly used chemotherapy
utilizing the SEER-Medicare data partition patients according to a specific treatment approach. We
envision that this model could be combined with future clinically validated gene signatures for a more
refined assessment of patient risk.
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Chapter3:
Effect of COPD and Chemotherapy on an
Integrative Prognostic Model
Joseph Putila, Nancy Lan Guo

Abstract
Background: Selection of an appropriate course of therapy is a key factor in prolonging survival in lung
cancer, and relies heavily on an accurate assessment of a patient’s risk of recurrence. This analysis
extends the previously described prognostic model through the use of data on chemotherapy and comorbidities, further refining prognostication.
Methods: Data on 34,203 adenocarcinoma and 26,967 squamous cell carcinoma patients were used to
determine the contribution of Chronic Obstructive Pulmonary Disease (COPD) to prognostication in 30
treatment combinations. A Cox model including COPD was estimated on 1000 bootstrap samples, with
the resulting model assessed on ROC, Brier Score, Harrell’s C, and Nagelkerke’s R2 metrics in order to
highlight improvements in prognostication over a previously defined model without COPD.
Results: The addition of COPD to the model was shown to improve prognostication in patient groups
covering multiple treatment combinations including those treated with and without chemotherapy. For
adenocarcinoma patients, there was an improvement seen in the overall patient sample and in patients
without chemotherapy, including those receiving surgery only. For squamous cell carcinoma, an
improvement was seen in both the overall patient sample and in patients receiving multiple types of
chemotherapy. In many cases these improvements persisted in several of the treatment subsets on
multiple measures. COPD was also able to stratify patients into significantly different high and low-risk
groups independent of other factors in stage and treatment sub-sets.
Significance: Although COPD is known to influence the treatment received, the results suggest that
those with the disorder are at higher risk when compared to patients receiving a similar treatment. This
extension of the previously described prognostic model to include COPD status and chemotherapy was
able to significantly improve prognostication.
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Introduction
One of the most important factors influencing the survival of patients with lung and bronchus
cancers is the selection of an appropriate course of therapy based on an accurate assessment of patient
risk. However, the selection of a course of therapy is currently based largely on tumor stage alone
despite the contribution of other factors to patient survival. In particular, comorbidities such as COPD
can have a significant effect on long-term survival due to varying treatment candidacy, increased
complication rate, or decreased treatment efficacy (Janssen-Heijnen et al., 1998; Janssen-Heijnen et al.,
2004; Kiri et al., 2010), and the prevalence of this disease is elevated in lung cancer patients
independent of smoking status (Young et al., 2009). A major impediment is determining the
contribution of each of these factors in a comprehensive prognostic model, rather than as independent
effects.
Comorbidities which affect lung function, such as COPD, are likely to influence post-operative
survival independent of their effects on surgical candidacy due to the possibility of decreased lung
function. The Forced Expiratory Volume in 1 second (FEV1) of a patient, a potential indicator of COPD,
was found to be a significant prognostic factor in a model controlling for other clinical variables such as
nodal status (Dehing-Oberije et al., 2008; Dehing-Oberije et al., 2009). Although COPD and lung cancer
are often seen together in patients due to their shared association with smoking behavior, neither
condition is a clinical end-point for the other. As such, COPD remains viable as a potential prognostic
factor despite any shared similarity with lung cancer in the etiology of the disease.
Previously, we described a prognostic model utilizing similar data derived from the SEER cancer
registry initiative (Putila et al., 2011) designed to address the problem of developing an integrative
model. The previous approach utilized clinical and demographic variables in a single model to achieve
superior prognostication over a similar model using stage alone. The model was however limited by the
data in that the use of specific chemotherapies and the presence of comorbidities could not be
determined. This analysis extends the previous analysis by utilizing patient records from the linked
SEER-Medicare database. These additional data allow for the role of COPD in prognostication to be
determined across combinations of surgical, radiological, and chemotherapeutic treatments (Elixhauser
et al., 1998; Warren et al., 2002b).
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Materials and Methods
Patient data was obtained from the linked SEER-Medicare database, a combination of
population-based registry data and billing histories for patients covered by Medicare. In short, data
from participating Surveillance Epidemiology and End-Results (SEER) registries were linked with
Medicare data through the use of social security number, census tract, age, and other identifying
variables(Warren et al., 2002b). The resulting data contain information on treatments administered, comorbidities present in the patient, clinical presentation, survival, and demographics. Criteria for
inclusion in this analysis were a diagnosis of lung or bronchus cancer between 1991 and 2005, and
complete information on age, race, gender, tumor grade and stage, as well as valid follow-up and billing
history. This set of patients was further refined to only include those with tumors broadly classifiable as
either squamous cell carcinoma or adenocarcinoma. Cases reported solely from autopsy or death
certificate were excluded. In total, 34,203 patients with adenocarcinomas and 26,967 patients with
squamous cell carcinomas met these criteria.
The administration of chemotherapy was determined using Healthcare Common Procedure
Coding System (HCPCS) codes in combination with International Classification of Diseases (ICD) codes.
For each patient, all records were searched for entries with an HCPCS code indicating that
chemotherapy was administered. These entries were then cross referenced with the ICD primary and
secondary diagnosis codes for that entry to ensure that the agent was being administered for the
treatment of lung or bronchus cancers. Four specific agents, cisplatin, carboplatin, docetaxel, and
paclitaxel were considered in addition to a broad group covering a variety of chemotherapeutic agents.
Patients were also analyzed according to variable administration of curative surgery and
radiological treatment. Five groups were formed on the basis of surgical and radiological treatments; a
group containing all patients regardless of treatment, a group for patients having surgery without
radiation, another for those having radiation without surgery, a group with both surgery and radiation, a
group of patients without any treatment listed. Surgical and radiological treatment group assignments
were based on the presence of any curative treatment of that type in the SEER portion of the data.
Comorbidities were measured as components of a version of the Charlson Comorbidity Index
(CCI) adapted for use with administrative data (Charlson et al., 1987; Deyo et al., 1992; Klabunde et al.,
2000; Romano et al., 1993). Comorbidities were determined using code available from the NCI designed
specifically for this SEER-Medicare dataset
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(http://healthservices.cancer.gov/seermedicare/program/comorbidity.html), under the assumption that
the presence of a treatment for a specific disease in the billing history was indicative of its presence in
the patient at the time. All claims out to three years prior to the diagnosis with lung cancer were
analyzed for specific sets of ICD-9 codes indicative of one of the conditions listed in the CCI. Upon
finding a relevant ICD code for any of the 18 conditions included in the index, patients were flagged as
being positive for the corresponding condition. The determination of chemotherapy use and comorbidities was done using SAS version 9.2 in the PC environment.
Patient age, race, and sex were identified using information in the SEER portion of the data, with
Black and Asian/Pacific Islander patients being compared to Whites as a reference group. Tumor grade
was also identified from the SEER portion of the data. Tumor grades 1 and 2 were grouped together and
served as a reference group for grades 3 and 4, which were also grouped in the Cox models. Tumor
stage was listed in the SEER portion of the data in either the 3rd or 6th Edition of the AJCC staging system.
Records coded using the 6th Edition were able to be recoded to the 7th Edition provided that they had
complete and valid information on tumor size, extension, nodal involvement, and distant metastases.
Tumor stage I was used as a reference group in the Cox models. The number and distribution of patient
characteristics is detailed in Table 3.1.
Each co-morbid condition was assessed as an independent predictor of survival using Cox
proportional hazards modeling in patients treated with surgery but without chemotherapy or radiation
indicated in order to isolate the effects of comorbidity from those of disparate treatment benefit or
treatment candidacy (Table 3.2). Additionally, the presence of COPD as determined via the analysis of
administrative records was assessed as an independent predictor of survival by testing for significant
stratification of Kaplan-Meier survival curves. Patients were split into two outcome groups based on
COPD status, and separate survival curves were estimated and plotted (Figure 3.1). Again, only patients
receiving surgery without radiation or chemotherapy were included in order to better isolate the effect
of COPD from other effects resulting from disparate treatment candidacy. The significance of the
difference in survival was determined using the G-rho family of tests, with a p-value less than 0.05
indicating a significant difference in the survival curves estimated for the two groups being compared.
Patients were then further split into stage groups and the effect of COPD in these subsets was assessed
for each group. A selection of these results can be seen in Figures 3.2 through 3.7.
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Table 3.1. Distribution of demographic and clinical characteristics of patients diagnosed with adenocarcinoma or squamous cell carcinoma in the original
and recoded AJCC staging systems.

Variable
Stage
1
2
3a
3b
4
Grade
1
2
3
4
Age, Mean(SD)
Race
White
Black
Asian/Pac.
Islander
Sex
Male
Female
+COPD Diagnosis

AJCC 3rd

Adenocarcinoma
AJCC 6th

AJCC 7

9,510 (35.6%)
1,475 (5.5%)
2,610 (9.8%)
4,638 (17.3%)
8,516 (31.8%)

3,127 (42%)
580 (7.8%)
661 (8.9%)
919 (12.3%)
2,167 (29.1%)

2,371 (33.3%)
1,400 (19.7%)
1,145 (16.1%)
438 (6.2%)
1,762 (24.8%)

7,110 (33%)
1,272 (5.9%)
3,074 (14.2%)
4,928 (22.8%)
5,188 (24.0%)

1,968 (36.5%)
574 (10.6%)
650 (12%)
907 (16.8%)
1296 (24%)

1,466 (28.6%)
958 (18.7%)
1,114 (21.7%)
496 (9.7%)
1,089 (21.3%)

3,436 (12.8%)
8,780 (32.8%)
13,885 (51.9%)
648 (2.4%)
73.4 (7.2)

1,189 (16%)
2,892 (38.8%)
3,235 (43.4%)
138 (1.9%)
74.0 (7.6)

1,143 (16%)
2,800 (39.3%)
3,044 (42.8%)
129 (1.8%)
73.9 (7.6)

1,000 (4.6%)
8,384 (38.9%)
11,713 (54.3%)
475 (2.2%)
73.5 (6.9)

191 (3.5%)
2,284 (42.3%)
2,850 (52.8%)
70 (1.3%)
74.1 (7.4)

180 (3.5%)
2,182 (42.6%)
2,694 (52.6%)
67 (1.3%)
74.2 (7.3)

23218 (86.8%)
1945 (7.3%)

6,515 (87.4%)
531 (7.1%)

6,219 (87.4%)
508 (7.1%)

18,456 (85.6%)
2,232 (10.3%)

4,727 (87.6%)
486 (9%)

4,490 (87.6%)
459 (9.0%)

1586 (5.9%)

408 (5.5%)

389 (5.5%)

884 (4.1%)

182 (3.4%)

174 (3.4%)

13678 (51.1%)
13071 (48.9%)
7948 (29.7%)

3,556 (47.7%)
3,898 (52.3%)
2,647 (35.5%)

3,372 (47.4%)
3,744 (52.6%)
2,538 (35.7%)

14,111 (65.4%)
7,461 (34.6%)
8,521 (39.5%)

3,370 (62.5%)
2,025 (37.5%)
2,568 (47.6%)

3,186 (62.3%)
1,937 (37.7%)
2,431 (47.6%)

th

AJCC 3rd

Squamous Cell Carcinoma
AJCC 6th
AJCC 7th
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The distributions of COPD and other variables in the original model were assessed in patients
with very long and very short survival, relative to other patients, to determine if certain characteristics
were disparate between groups of patients with varied survival. This was accomplished by partitioning
patients based on survival time and status, then using a t-test or test of proportions to compare the
distributions of variables between each group. Again, only those patients who were treated with
surgery without radiation or chemotherapy were included. Long survival was defined as greater than 60
months for the original 3rd Edition staging, and greater than 24 months for the 6th and recoded 7th
Edition groups due to shortened follow-up. Short survival was defined as less than 24 months for the
original 3rd Edition staging, and less than 12 months for the 6th and recoded 7th Edition groups (Table
3.3).
Cox modeling was then used to estimate a proportional hazards model for use in quantitatively
assessing patient risk given multiple variables. Two separate models were estimated: a Full model
containing information on patient age, race, sex, tumor grade and stage, and a COPD model containing
the same variables with an additional indicator of the presence of COPD. For both the Full and COPD
models, a total of one-thousand Cox proportional-hazard models were estimated using bootstrapped
samples equal in size to the original patient cohort. The distributions of coefficients were assessed for
normality, and the mean of each coefficient was taken. This set of coefficients formed the final model
for each approach.
The models were then assessed on a total of four metrics; area under an ROC curve, Brier Score,
Harrell’s c, and Nagelkerke’s R2. The ROC measure represents the area under an integrated ROC curve
out to 36 months for the original 3rd Edition AJCC staging, and 24 months for the 6th and recoded 7th
Edition AJCC staging. The Harrell’s c measure is similar to the ROC measure, but takes into account the
aspect of time. Nagelkerke’s R2 is a generalized form of the coefficient of determination (R2) suitable for
survival models. The ROC, c-statistic, and R2 measures all range from 0 to 1, with higher scores
indicating better performance. The Brier score is a measure of the accuracy of survival predictions, and
ranges from 0 to 1 with lower scores being better. Similar to the ROC measure, the Brier score was
calculated at 36 months for the original AJCC staging and 24 months for the recoded AJCC staging.
These estimations were performed on 100 bootstrapped patient cohorts with a two-tailed T test being
used to assess significant differences between models on each test. All model estimations and
assessments were performed using R version x64 2.15.0, with the survival, risksetAUC, Design, rms, pec,
and Hmisc packages.
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The final models to be used in the online tool were constructed using the coefficients estimated
earlier for the models containing tumor stage, grade, age, race, sex, and COPD status. A total of six
models, one for each AJCC Staging Edition and histology combination, were constructed. Cutoffs for
each AJCC Edition and histology group were determined by selecting two cutoffs to partition patients
into High and Low-Risk groups across the range of Hazard Scores in the total patient population and
testing the difference in survival between the Full and Stage Only models in an iterative manner. The
final cutoffs represent points at which the Full model shows the greatest improvement in selecting both
High and Low-Risk patients in that group. This stratification is represented in Figure 3.8. For each new
patient entered using the tool, the Hazard Score is estimated using the coefficients for each variable in
the appropriate model. The final coefficients and graphical representation of long-term survival as
determined by Hazard Score are shown for each model in Figures 3.9 through 3.14. A representative
image of the web-based application of the final prognostic model can be seen in Figure 3.15.

Results
COPD showed significant prognostic ability on multiple measures, both as an independent
predictor and in the presence of other predictors. Other co-morbid conditions also showed promise as
independent predictors in a Cox model (Table 3.2). As an independent predictor, COPD status alone was
able to significantly stratify patients into high and low-risk groups (p<0.05) in four of six groups (Figure
3.1), although small sample size in the newer squamous cell carcinoma groups may have impeded
achieving a significant stratification. The stratification in squamous cell carcinoma cases coded in the
original 6th Edition and those recoded to the 7th Edition of AJCC staging was not significant despite a
small degree of separation, with COPD patients having slightly diminished survival concordant with the
other significant groups. In the significant cases, those without COPD showed consistently and
significantly better survival when compared to those with COPD across the entire length of available
follow-up, indicating that the effects of COPD are manifested in both long and short-term survival
(Figure 3.1).
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Table 3.2. Result of modeling survival in a model with each comorbid condition as an independent predictor.
Shown are conditions which confer significantly poorer survival in one or both of the histologies considered
when the sample was restricted to patients receiving surgery without radiation or chemotherapy.

Adenocarcinoma
Squamous Cell
Condition Odds Ratio p-value Odds Ratio
p-value
Congestive Heart Failure
1.37
<0.0001*
1.27
0.0003*
Peripheral Vascular Disease
1.22
0.0020*
1.03
0.7234
Cerebrovascular Disease
1.16
0.0152*
1.06
0.3874
COPD
1.24
<0.0001*
1.11
0.0140*
Diabetes with sequelae
1.26
0.0186*
1.06
0.5964
Chronic Renal Failure
1.18
0.4083
1.57
0.0002*
Cirrhosis
0.74
0.3000
1.95
0.0024*
Gastrointestinal Ulcers
1.33
0.0193*
1.22
0.1337

Table 3.3. Methodology for assigning patients to outcome groups based on survival time and status, for use in
rd
th
comparing the prevalence of COPD in the AJCC 3 Edition staging scheme (A) and AJCC 6 Edition and recoded
th
7 Edition (B). Survival status is based on disease (lung and bronchus cancer) specific criteria.

A. Survival Time/Status
<24 Months
>=60 Months

Alive
Intermediate
Long

Deceased
Short
Long

B. Survival Time/Status
<12 Months
>=24 Months

Alive
Intermediate
Long

Deceased
Short
Long
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Figure 3.1. Survival curves generated for patients with and without COPD among those treated with surgery
alone.
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Figure 3.2. Effect of COPD in Adenocarcinoma AJCC 3 Edition stage and treatment sub-groups. For each group,
a clear and significant difference between the survival curves for patients with and without COPD can be seen,
with patients identified as having COPD experiencing significantly poorer survival compared to those without
COPD.
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Figure 3.3. Effect of COPD in Adenocarcinoma AJCC 6 Edition stage and treatment sub-groups. For each group,
patients without COPD tend to experience longer survival when compared to patients with COPD, although the
difference is not significant in some cases shown.
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Figure 3.4. Effect of COPD in Adenocarcinoma AJCC 7 Edition stage and treatment sub-groups. For each group
treated without chemotherapy, a clear and significant difference between the survival curves for patients with
and without COPD can be seen, with patients identified as having COPD experiencing significantly poorer
survival compared to those without the disease. The difference in survival for patients treated with systemic
therapy was not significant, but trended toward patients with COPD having poorer survival.
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Figure 3.5. Effect of COPD in Squamous Cell AJCC 3 Edition stage and treatment sub-groups. For each group, a
clear and significant difference between the survival curves for patients with and without COPD can be seen,
with patients identified as having COPD experiencing significantly poorer survival compared to those without
the disease.
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Figure 3.6. Effect of COPD in Squamous Cell AJCC 6 Edition stage and treatment sub-groups. For the group
shown, a clear and significant difference between the survival curves for patients with and without COPD can be
seen, with patients identified as having COPD experiencing significantly poorer survival compared to those
without the disease.
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Figure 3.7. Effect of COPD in Squamous Cell AJCC 7 Edition stage and treatment sub-groups. For each group, a
clear and significant difference between the survival curves for patients with and without COPD can be seen,
with patients identified as having COPD experiencing significantly poorer survival compared to those without
the disease.

The proportion of patients with COPD between those with relatively long and short survival was
also assessed. Two survival cutoffs were used to split patients into three groups of short, intermediate,
and long survival in order to test for differences in the distribution of each prognostic factor between
groups of patients with relatively different survival. The difference in the prevalence of COPD between
the short and long survival groups was assessed using a test of proportions. This test showed that COPD
was much more prevalent in patients with relatively short survival when compared to those surviving
relatively longer (Table 3.4). This was true for each histology and coding scheme, despite differences in
cutoffs and length of follow-up between the original and recoded staging systems. When the same test
was performed for the other covariates similar results were seen, with factors previously seen to favor
increased or diminished survival being disparate between the groups. These results are summarized in
Tables 3.4 through 3.9.
Patients were able to be split into high and low-risk groups with significantly different survival
curves using COPD status alone in a variety of treatment and stage sub-groups. For adenocarcinoma
patients staged using the original 3rd Edition staging, there was a significant difference in the survival of
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Stage I patients treated with surgery alone. There was also a significant difference seen in Stage 2 and
3a patients treated with surgery with a platinum and taxane or without systemic therapy (p<0.05). A
fourth stratification in Stage 2 and 3a patients treated with radiation and systemic therapy was also
present (p<0.05, Figure 3.2).
In the group of patients staged using the original 6th Edition, Stage 2 and 3a radiation patients
treated both with and without systemic therapy trended toward a similar stratification but did not
achieve significance (p>0.05). A similar trend was observed for Stage 2 and 3a surgical patients treated
with systemic therapy, although the degree of separation was again not significant (p>0.05). The group
of stage 1 surgical patients treated without systemic therapy did however achieve a significant
stratification (p=0.0111, Figure 3.3).
In the group of adenocarcinoma patients recoded to AJCC 7th Edition staging, there was a
significant difference in survival between patients with and without COPD in Stage I surgical patients
treated without systemic therapy (p=0.0374). This same difference was also present in Stage 2 and 3a
surgical patients treated without systemic therapy (p=0.0101). There was a similar trend in the group of
Stage 2 and 3a patients treated with surgery and systemic therapy, but the difference in survival was not
significant for any of the systemic therapy groups (p>0.05). The group of Stage 2 and 3a patients
without COPD also experienced significantly better survival when treated with radiation without
systemic therapy (p=0.0025, Figure 3.4).
In squamous cell patients staged using the original 3rd Edition the difference in survival when
stratifying on COPD status for Stage I surgical patients treated without systemic therapy was significant,
with patients having COPD again experiencing poorer survival (p=0.0002). There was also a significant
stratification in the corresponding group of Stage I surgical patients treated with systemic therapy
(p<0.05). COPD Was able to produce a significant stratification in Stage 2 and 3a patients treated with
systemic therapy in both the surgical and radiation groups (p<0.05, Figure 3.5). In patients staged using
the original 6th Edition, COPD was able to produce a single stratification in Stage 2 and 3a surgical
patients treated without systemic therapy (p=0.0091, Figure 3.6).
In the recoded 7th Edition staging, there were two groups where COPD was able to stratify
patients. The first was in Stage 2 and 3a patients treated with surgery without any systemic therapy,
with COPD patients having poorer survival (p=0.0058). The same pattern was observed in Stage 2 and
3a patients treated with radiation without any systemic therapy (p=0.0350, Figure 3.5).
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Table 3.4. Proportion of patients with COPD in long and short-survival groups. A test of proportions was used to
assess significant differences in the prevalence of COPD in the two survival groups created from patients treated
with surgery without radiation or chemotherapy.

Group
Adenocarcinoma 3rd

Cutoffs
Short
Long
<24 mo >= 60 mo

% COPD
Short
Long
34.2%
24.2%

P-Value
<0.0001

Adenocarcinoma 6th

<12 mo

>= 24 mo

39.0%

32.2%

0.0438

Adenocarcinoma 7

th

<12 mo

>= 24 mo

39.5%

32.2%

0.0326

Squamous Cell 3

rd

<24 mo

>= 60 mo

39.9%

34.0%

0.0005

Squamous Cell 6

th

<12 mo

>= 24 mo

53.5%

44.9%

0.0368

Squamous Cell 7

th

<12 mo

>= 24 mo

53.6%

44.8%

0.0344

Table 3.5. Mean AJCC tumor stage in long and short-survival groups. A t-test was used to assess significant
differences in mean stage in the two survival groups created from patients treated with surgery without
radiation or chemotherapy.

Group
Adenocarcinoma 3rd

Cutoffs
Short
Long
<24 mo >= 60 mo

Mean Stage
Short
Long
2.03
1.17

P-Value
<0.0001

Adenocarcinoma 6th

<12 mo

>= 24 mo

2.22

1.29

<0.0001

Adenocarcinoma 7

th

<12 mo

>= 24 mo

2.26

1.42

<0.0001

Squamous Cell 3

rd

<24 mo

>= 60 mo

1.91

1.26

<0.0001

Squamous Cell 6

th

<12 mo

>= 24 mo

1.97

1.28

<0.0001

Squamous Cell 7

th

<12 mo

>= 24 mo

2.12

1.42

<0.0001

Table 3.6. Mean tumor grade in long and short-survival groups. A t-test was used to assess significant
differences in mean tumor grade in the two survival groups created from patients treated with surgery without
radiation or chemotherapy.

Group
Adenocarcinoma 3rd

Cutoffs
Short
Long
<24 mo >= 60 mo

Mean Grade
Short
Long
2.46
2.08

P-Value
<0.0001

Adenocarcinoma 6th

<12 mo

>= 24 mo

2.38

2.03

<0.0001

Adenocarcinoma 7

th

<12 mo

>= 24 mo

2.40

2.03

<0.0001

Squamous Cell 3

rd

<24 mo

>= 60 mo

2.53

2.50

0.1486

Squamous Cell 6

th

<12 mo

>= 24 mo

2.49

2.42

0.1374

Squamous Cell 7

th

<12 mo

>= 24 mo

2.42

2.50

0.1201
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Table 3.7. Mean patient age in long and short-survival groups. A t-test was used to assess significant differences
in patient age in the two survival groups created from patients treated with surgery without radiation or
chemotherapy.

Group
Adenocarcinoma 3rd

Cutoffs
Short
Long
<24 mo >= 60 mo

Mean Age
Short
Long
73.80
72.30

P-Value
<0.0001

Adenocarcinoma 6th

<12 mo

>= 24 mo

75.03

73.40

0.0029

Adenocarcinoma 7

th

<12 mo

>= 24 mo

74.85

73.42

0.0084

Squamous Cell 3

rd

<24 mo

>= 60 mo

73.85

72.13

<0.0001

Squamous Cell 6

th

<12 mo

>= 24 mo

74.80

73.34

0.001

Squamous Cell 7

th

<12 mo

>= 24 mo

74.82

73.35

0.0101

Table 3.8. Proportion of patients classified as API (top) or Black (bottom) in long and short-survival groups. A
test of proportions was used to assess significant differences in the prevalence of minority groups in the two
survival groups created from patients treated with surgery without radiation or chemotherapy.

Group
Adenocarcinoma 3rd

Cutoffs
Short
Long
<24 mo >= 60 mo

Race (API)
Short
Long
4.70%
5.70%

P-Value
0.1445

Adenocarcinoma 6th

<12 mo

>= 24 mo

6.18%

6.58%

0.9219

th

<12 mo

>= 24 mo

6.32%

6.50%

1

Squamous Cell 3rd

<24 mo

>= 60 mo

3.54%

3.51%

1

Squamous Cell 6

th

<12 mo

>= 24 mo

3.98%

2.95%

0.6176

Squamous Cell 7

th

<12 mo

>= 24 mo

4.00%

3.00%

0.606

Adenocarcinoma 7

Group
Adenocarcinoma 3rd

Cutoffs
Short
Long
<24 mo >= 60 mo

Race (Black)
Short
Long
6.40%
5.10%

P-Value
0.0865

Adenocarcinoma 6th

<12 mo

>= 24 mo

6.18%

4.96%

0.5221

Adenocarcinoma 7

th

<12 mo

>= 24 mo

6.32%

4.97%

0.4728

Squamous Cell 3

rd

<24 mo

>= 60 mo

8.03%

8.68%

0.5516

Squamous Cell 6

th

<12 mo

>= 24 mo

4.87%

6.69%

0.4324

Squamous Cell 7

th

<12 mo

>= 24 mo

4.91%

6.71%

0.4448
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Table 3.9. Proportion of male patients in the long and short-survival groups. A test of proportions was used to
assess significant differences in sex in the two survival groups created from patients treated with surgery
without radiation or chemotherapy.

Group
Adenocarcinoma 3rd

Cutoffs
Short
Long
<24 mo >= 60 mo

Sex (Male)
Short
Long
56.50% 39.90%

P-Value
<0.0001

Adenocarcinoma 6th

<12 mo

>= 24 mo

52.12%

40.94%

0.0014

Adenocarcinoma 7

th

<12 mo

>= 24 mo

52.17%

40.92%

0.0014

Squamous Cell 3

rd

<24 mo

>= 60 mo

68.31%

59.08%

<0.0001

Squamous Cell 6

th

<12 mo

>= 24 mo

64.16%

55.71%

0.03916

Squamous Cell 7

th

<12 mo

>= 24 mo

64.29%

55.62%

0.0350
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Model Improvement in Adenocarcinoma
When using the original 3rd Edition staging system the addition of COPD to the model resulted in
a significant improvement on the Harrell’s c-statistic in the total group of patients treated with any
treatment and those treated with surgery alone (p<0.05). This improvement on Harrell’s c persisted for
those groups when only patients treated without indication of chemotherapy were considered. There
were also improvements with the addition of COPD on the ROC measure in patients treated without
indication of chemotherapy (p<0.05). There were no significant improvements in either the
Nagelkerke’s R2 measure or the Brier score.
In the group of patients coded using the 6th Edition staging, there was a significant improvement
in on the Harrell’s c measure in the total group of patients (p=0.0480). There was an additional
improvement in patients treated with surgery regardless of indication of chemotherapy on the ROC
measure (p=0.0475). As was the case with the 3rd Edition staging system, there were no significant
improvements in either the Nagelkerke’s R2 measure or the Brier Score.
When patients were recoded to the 7th Edition staging, there was a significant improvement on
the ROC measure in the total group of patients (p=0.0436) which persisted when only patients receiving
surgery regardless of indication of chemotherapy were considered (p=0.0326). These results strongly
indicate that the greatest improvement in prognostication occurred in patients without indication of
chemotherapy, with a concordant improvement in the entire patient sample. The results for the three
staging systems are summarized in Tables 3.10 through 3.13. Patient survival and the final Cox model
coefficients for each staging system can be seen in Figures 3.9 through 3.11.
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Table 3.10. P-values estimated by comparing the Harrell’s c-statistics from 100 bootstrapped samples using the
Cox model generated on the entire patient sample for the original Comprehensive model, and the same model
estimated with a COPD indicator added. Significant values are highlighted in yellow, with values showing
degradation in prognostication with the addition of COPD bolded and italicized.

Any Treatment
Surgery Only
Radiation Only
Surg + Rad
No Treatment

Total
0.0016
0.0043
0.3493
0.8379
0.3143

No
Chemo
0.0002
0.0028
0.2363
0.8601
0.0702

Any Treatment
Surgery Only
Radiation Only
Surg + Rad
No Treatment

Total
0.0480
0.3046
0.1499
0.6971
0.0700

No
Chemo
0.0856
0.2051
0.6973
0.7273
0.1956

Any Treatment
Surgery Only
Radiation Only
Surg + Rad
No Treatment

Total
0.0500
0.2257
0.4322
0.6118
0.0857

No
Chemo
0.0711
0.1882
0.9241
0.7944
0.3129

Adenocarcinoma 3rd
Any Chemo Platinum Paclitaxel Plat+Tax
0.7142
0.7462
0.7217
0.5776
0.9519
0.7105
0.8789
0.8064
0.7388
0.8425
0.2166
0.6873
0.7690
0.8968
0.9997
0.9028
0.4461
0.3056
0.7928
0.1980
Adenocarcinoma 6th
Any Chemo Platinum Paclitaxel Plat+Tax
0.3955
0.5910
0.9437
0.7413
0.8345
0.7036
0.9168
0.6176
0.2356
0.7225
0.5726
0.6144
0.5079
0.4342
0.9827
0.6161
0.4042
0.7254
0.4114
0.6656
Adenocarcinoma 7th
Any Chemo Platinum Paclitaxel Plat+Tax
0.3876
0.6259
0.7937
0.6621
0.6936
0.6574
0.9999
0.7558
0.8388
0.7593
0.4598
0.9601
0.6889
0.5453
0.7461
0.7422
0.3658
0.4242
0.6381
0.4773
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Table 3.11. P-values estimated by comparing the Nagelkerke’s R statistic from 100 bootstrapped samples using
the Cox model generated on the entire patient sample for the original Comprehensive model, and the same
model estimated with a COPD indicator added. Significant values are highlighted in yellow, with values showing
degradation in prognostication with the addition of COPD bolded and italicized.

Any Treatment
Surgery Only
Radiation Only
Surg + Rad
No Treatment

Total
0.1584
0.0866
0.5638
0.5914
0.4754

No
Chemo
0.1201
0.1202
0.7560
0.6995
0.1228

Any Treatment
Surgery Only
Radiation Only
Surg + Rad
No Treatment

Total
0.2176
0.0874
0.1130
0.4996
0.3263

No
Chemo
0.1477
0.2201
0.1663
0.9854
0.6722

Any Treatment
Surgery Only
Radiation Only
Surg + Rad
No Treatment

Total
0.0814
0.0679
0.2211
0.5132
0.2814

No
Chemo
0.3379
0.1815
0.3464
0.9514
0.5350

Adenocarcinoma 3rd
Any Chemo Platinum Paclitaxel Plat+Tax
0.9228
0.9007
0.9004
0.8727
0.8685
0.9079
0.8471
0.8309
0.4240
0.4644
0.2454
0.5246
0.8545
0.8178
0.9995
0.8949
0.5587
0.5011
0.5585
0.2461
Adenocarcinoma 6th
Any Chemo Platinum Paclitaxel Plat+Tax
0.6948
0.8449
0.9706
0.9137
0.5911
0.5291
0.9314
0.6899
0.8211
0.9646
0.5765
0.6126
0.2297
0.1906
0.9444
0.9301
0.7703
0.8269
0.4565
0.9344
Adenocarcinoma 7th
Any Chemo Platinum Paclitaxel Plat+Tax
0.5324
0.6550
0.6325
0.5860
0.5138
0.3998
0.9427
0.4235
0.9340
0.7292
0.9713
0.3919
0.4026
0.4431
0.9588
0.8120
0.4753
0.6372
0.8534
0.6812
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Table 3.12. P-values estimated by comparing the area under an Integrated ROC curve out to 36 months for the
rd
th
th
3 Edition and 24 months for the 6 and recoded 7 Edition from 100 bootstrapped samples using the Cox
model generated on the entire patient sample for the original Comprehensive model, and the same model
estimated with a COPD indicator added. Significant values are highlighted in yellow, with values showing
degradation in prognostication with the addition of COPD bolded and italicized.

Any Treatment
Surgery Only
Radiation Only
Surg + Rad
No Treatment

Total
0.1453
0.0980
0.2674
0.6427
0.2912

No
Chemo
0.0404
0.0269
0.3197
0.6579
0.0497

Any Treatment
Surgery Only
Radiation Only
Surg + Rad
No Treatment

Total
0.0834
0.0475
0.0908
0.4155
0.2379

No
Chemo
0.1222
0.1127
0.1167
0.9416
0.4202

Total
0.0436
0.0326
0.2037
0.6475
0.1568

No
Chemo
0.1846
0.0630
0.4139
0.7967
0.2826

Any Treatment
Surgery Only
Radiation Only
Surg + Rad
No Treatment

Adenocarcinoma 3rd
Any Chemo Platinum Paclitaxel Plat+Tax
0.8635
0.7894
0.8856
0.7661
0.9158
0.7657
0.7520
0.8878
0.5190
0.5322
0.2366
0.4830
0.9475
0.9902
0.9664
0.9147
0.5786
0.4414
0.7798
0.3310
Adenocarcinoma 6th
Any Chemo Platinum Paclitaxel Plat+Tax
0.5936
0.7844
0.9602
0.9752
0.5290
0.5653
0.9689
0.6005
0.6157
0.8712
0.8276
0.7574
0.3495
0.2381
0.9486
0.7450
0.7530
0.9481
0.6597
0.8425
Adenocarcinoma 7th
Any Chemo Platinum Paclitaxel Plat+Tax
0.4478
0.7310
0.8017
0.7131
0.3348
0.3295
0.7815
0.5313
0.8399
0.9630
0.8433
0.6449
0.4103
0.3634
0.8988
0.8784
0.5004
0.7161
0.9540
0.5240
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Table 3.13. P-values estimated by comparing the Brier score at 36 months for the 3 Edition and 24 months for
th
th
the 6 and recoded 7 Edition from 100 bootstrapped samples using the Cox model generated on the entire
patient sample for the original Comprehensive model, and the same model estimated with a COPD indicator
added. Significant values are highlighted in yellow, with values showing degradation in prognostication with the
addition of COPD bolded and italicized.

Any Treatment
Surgery Only
Radiation Only
Surg + Rad
No Treatment

Total
0.0801
0.3738
0.7452
0.9379
0.8303

No
Chemo
0.1161
0.3481
0.7439
0.8855
0.7250

Any Treatment
Surgery Only
Radiation Only
Surg + Rad
No Treatment

Total
0.1731
0.6337
0.3224
0.6245
0.6505

No
Chemo
0.1335
0.6007
0.2946
0.6985
0.6440

Total
0.1273
0.5045
0.3143
0.8202
0.5261

No
Chemo
0.0677
0.3737
0.2295
0.8252
0.4674

Any Treatment
Surgery Only
Radiation Only
Surg + Rad
No Treatment

Adenocarcinoma 3rd
Any Chemo Platinum Paclitaxel Plat+Tax
0.6341
0.7535
0.6077
0.6832
0.7197
0.7455
0.6505
0.7429
0.8391
0.8165
0.7534
0.8005
0.8526
0.9518
0.9409
0.8444
0.9825
0.9604
0.9445
0.8964
Adenocarcinoma 6th
Any Chemo Platinum Paclitaxel Plat+Tax
0.8574
0.7562
0.9032
0.6800
0.8431
0.9083
0.9250
0.8183
0.7990
0.8363
0.9905
0.7586
0.9679
0.9779
0.9738
0.7066
0.9686
0.7483
0.7406
0.9309
Adenocarcinoma 7th
Any Chemo Platinum Paclitaxel Plat+Tax
0.9072
0.5518
0.9375
0.5797
0.8554
0.9413
0.9563
0.8841
0.8211
0.9512
0.8165
0.6344
0.9340
0.9979
0.9321
0.7037
0.8933
0.7485
0.7839
0.9535
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Model Improvement in Squamous Cell Carcinoma
Using the original AJCC 3rd Edition coding scheme, there were multiple treatment groups which
showed a significant improvement in prognostication with the addition of COPD to the model. When
any combination of surgical or radiological treatment was considered regardless of indication of
chemotherapy, there was a significant improvement in the total sample on the Harrell’s c-statistic
(p=0.0130). This improvement persisted when only considering patients treated with any chemotherapy
(p=0.0244) or with a platinum-based agent (p=0.0125, Table 3.14). A similar improvement was seen in
patients treated with a platinum-based agent or with a platinum-based agent and a taxane and any
other surgical or radiological treatment for Nagelkerke’s R2 and ROC (p<0.05, Tables 3.15 and 3.16). The
addition of COPD to the model was able to significantly improve prognostication on Harrell’s c-statistic
in surgical patients across the range of chemotherapy sub-groups (p<0.05). There was also a significant
improvement on the Brier score when all patients were considered (p=0.0239, Table 3.17).
In patients staged using the 6th Edition there was a significant degradation in model
performance on Harrell’s c-statistic in patients without an indication of treatment (p=0.0089). There
were not any further differences in other measures for this staging system. When the patients were
recoded using the AJCC 7th Edition criteria the difference in survival was again less pronounced than
when using the original 3rd Edition staging criteria. There was a single significant improvement on the
Brier score for patients treated without chemotherapy (p=0.0489). These results are summarized in
Tables 3.14 through 3.17. The final model used and a representation of survival for squamous cell
carcinoma patients can be seen in Figures 3.12 through 3.14.
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Table 3.14. P-values estimated by comparing the Harrell’s c-statistics from 100 bootstrapped samples using the
Cox model generated on the entire patient sample for the original Comprehensive model, and the same model
estimated with a COPD indicator added. Significant values are highlighted in yellow, with values showing
degradation in prognostication with the addition of COPD bolded and italicized.

Any Treatment
Surgery Only
Radiation Only
Surg + Rad
No Treatment

Total
0.0130
0.0006
0.4007
0.3112
0.3427

No
Chemo
0.0884
0.0107
0.8252
0.1602
0.2802

Any Treatment
Surgery Only
Radiation Only
Surg + Rad
No Treatment

Total
0.6265
0.8196
0.8807
0.8865
0.0089

No
Chemo
0.4355
0.9442
0.9912
0.9543
0.3086

Any Treatment
Surgery Only
Radiation Only
Surg + Rad
No Treatment

Total
0.3653
0.5885
0.9159
0.9691
0.0686

No
Chemo
0.1168
0.3530
0.8404
0.9854
0.4795

Squamous Cell 3rd
Any
Chemo
Platinum Paclitaxel Plat+Tax
0.0244
0.0125
0.1852
0.0571
0.0058
0.0077
0.0333
0.0263
0.1644
0.0867
0.2864
0.2079
0.7178
0.6892
0.5738
0.9322
0.4459
0.2366
0.6742
0.3606
Squamous Cell 6th
Any
Chemo
Platinum Paclitaxel Plat+Tax
0.6450
0.6121
0.9647
0.6468
0.2354
0.1670
0.6093
0.1985
0.8581
0.7801
0.7409
0.9108
0.6688
0.9064
0.9892
0.9165
0.4642
0.2662
0.6188
0.4358
Squamous Cell 7th
Any
Chemo
Platinum Paclitaxel Plat+Tax
0.7176
0.4349
0.9719
0.4815
0.3557
0.1124
0.5362
0.1533
0.9850
0.9178
0.6276
0.8035
0.6027
0.2893
0.1240
0.0891
0.4162
0.0971
0.3220
0.2295
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Table 3.15. P-values estimated by comparing the Nagelkerke’s R statistic from 100 bootstrapped samples using
the Cox model generated on the entire patient sample for the original Comprehensive model, and the same
model estimated with a COPD indicator added. Significant values are highlighted in yellow, with values showing
degradation in prognostication with the addition of COPD bolded and italicized.

Any Treatment
Surgery Only
Radiation Only
Surg + Rad
No Treatment

Total
0.1014
0.1290
0.6920
0.5961
0.7813

No
Chemo
0.4553
0.2859
0.6309
0.2976
0.5202

Any Treatment
Surgery Only
Radiation Only
Surg + Rad
No Treatment

Total
0.2640
0.5186
0.8845
0.6827
0.5641

No
Chemo
0.3448
0.3857
0.8187
0.6423
0.7819

Any Treatment
Surgery Only
Radiation Only
Surg + Rad
No Treatment

Total
0.2618
0.4343
0.9445
0.4112
0.8134

No
Chemo
0.3960
0.2752
0.9359
0.6121
0.8734

Squamous Cell 3rd
Any
Chemo
Platinum Paclitaxel Plat+Tax
0.1107
0.0229
0.1063
0.0286
0.1533
0.0674
0.1132
0.0873
0.0984
0.0986
0.2469
0.3527
0.8073
0.8086
0.2950
0.5920
0.5303
0.3370
0.9604
0.4286
Squamous Cell 6th
Any
Chemo
Platinum Paclitaxel Plat+Tax
0.8813
0.9451
0.7800
0.9195
0.7070
0.6605
0.9333
0.6305
0.6258
0.6304
0.9511
0.8436
0.7827
0.9323
0.9947
0.9845
0.8843
0.8359
0.8421
0.9833
Squamous Cell 7th
Any
Chemo
Platinum Paclitaxel Plat+Tax
0.9129
0.7735
0.7144
0.7504
0.8333
0.5224
0.9445
0.5179
0.8108
0.8063
0.7989
0.7206
0.6994
0.9492
0.7472
0.8845
0.6067
0.4735
0.7184
0.8235
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Table 3.16. P-values estimated by comparing the area under an Integrated ROC curve out to 36 months for the
rd
th
th
3 Edition and 24 months for the 6 and recoded 7 Edition from 100 bootstrapped samples using the Cox
model generated on the entire patient sample for the original Comprehensive model, and the same model
estimated with a COPD indicator added. Significant values are highlighted in yellow, with values showing
degradation in prognostication with the addition of COPD bolded and italicized.

Any Treatment
Surgery Only
Radiation Only
Surg + Rad
No Treatment

Total
0.0823
0.0141
0.9420
0.4149
0.7607

No
Chemo
0.3764
0.0718
0.5654
0.2187
0.5585

Any Treatment
Surgery Only
Radiation Only
Surg + Rad
No Treatment

Total
0.4187
0.3426
0.9241
0.6037
0.3139

No
Chemo
0.3237
0.2310
0.7226
0.6105
0.6181

Total
0.5050
0.2684
0.9690
0.3648
0.5305

No
Chemo
0.3799
0.1335
0.8683
0.5810
0.9266

Any Treatment
Surgery Only
Radiation Only
Surg + Rad
No Treatment

Squamous Cell 3rd
Any
Chemo
Platinum Paclitaxel Plat+Tax
0.0694
0.0383
0.1061
0.0412
0.0719
0.0553
0.0837
0.0811
0.0445
0.0600
0.1807
0.1807
0.8758
0.9028
0.5063
0.7268
0.5663
0.3072
0.7893
0.5403
Squamous Cell 6th
Any
Chemo
Platinum Paclitaxel Plat+Tax
0.8530
0.8345
0.7866
0.9525
0.7967
0.6588
0.9824
0.6829
0.5262
0.5636
0.9425
0.8440
0.6826
0.9929
0.9136
0.9764
0.9072
0.7603
0.7930
0.8559
Squamous Cell 7th
Any
Chemo
Platinum Paclitaxel Plat+Tax
0.8761
0.7701
0.8408
0.8796
0.8804
0.5706
0.8931
0.5738
0.6810
0.7237
0.8795
0.9022
0.6488
0.9048
0.9345
0.9024
0.6311
0.4731
0.7956
0.6966
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Table 3.17. P-values estimated by comparing the Brier score at 36 months for the 3 Edition and 24 months for
th
th
the 6 and recoded 7 Edition from 100 bootstrapped samples using the Cox model generated on the entire
patient sample for the original Comprehensive model, and the same model estimated with a COPD indicator
added. Significant values are highlighted in yellow, with values showing degradation in prognostication with the
addition of COPD bolded and italicized.

Any Treatment
Surgery Only
Radiation Only
Surg + Rad
No Treatment

Total
0.0239
0.4963
0.8111
0.2956
0.9588

No
Chemo
0.1278
0.6791
0.8972
0.1504
0.9889

Any Treatment
Surgery Only
Radiation Only
Surg + Rad
No Treatment

Total
0.1250
0.6225
0.7891
0.5036
0.9887

No
Chemo
0.0973
0.5191
0.9429
0.4595
0.8279

Total
0.0958
0.5874
0.7728
0.3010
0.9410

No
Chemo
0.0489
0.4013
0.8855
0.4205
0.7603

Any Treatment
Surgery Only
Radiation Only
Surg + Rad
No Treatment

Squamous Cell 3rd
Any
Chemo
Platinum Paclitaxel Plat+Tax
0.2410
0.1933
0.3010
0.2519
0.4563
0.3227
0.5379
0.3675
0.7258
0.7170
0.7838
0.8460
0.9136
0.7881
0.6282
0.6697
0.9258
0.9154
0.9958
0.9171
Squamous Cell 6th
Any
Chemo
Platinum Paclitaxel Plat+Tax
0.8682
0.9657
0.9154
0.8012
0.9971
0.9447
0.9593
0.9295
0.9727
0.9776
0.9543
0.8708
0.6109
0.8677
0.8574
0.8006
0.8543
0.8139
0.8145
0.8024
Squamous Cell 7th
Any
Chemo
Platinum Paclitaxel Plat+Tax
0.8356
0.9966
0.8708
0.8285
0.9734
0.8271
0.8533
0.8546
0.9251
0.9958
0.9410
0.9411
0.6278
0.8229
0.7921
0.7954
0.8705
0.7998
0.8941
0.7836
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Figure 3.8. Improvement in the Full model using COPD over Stage Alone. For each Kaplan-Meier plot, the three
pairs of lines represent the High, Intermediate, and Low-Risk groups defined for each of the two models shown.
The model using only AJCC Stage is shown in orange, while the Full model with COPD status added is shown in
blue. For each plot shown, the Full model with COPD status was able to produce a Low-Risk group with better
survival and a High-Risk group with poorer survival, with most cases being significant (p<0.05).
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Figure 3.9. Final model for Adenocarcinoma AJCC 3 Edition. Model coefficients used to determine the Hazard
Score for each patient are shown on the forest plot (right). Patient survival at 60 months for the total
population sample is shown for the range of Hazard Scores (left), with the risk-groups delimited by vertical bars.

th

Figure 3.10. Final model for Adenocarcinoma AJCC 6 Edition. Model coefficients used to determine the Hazard
Score for each patient are shown on the forest plot (right). Patient survival at 24 months for the total
population sample is shown for the range of Hazard Scores (left), with the risk-groups delimited by vertical bars.
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Figure 3.11. Final model for Adenocarcinoma AJCC 7 Edition. Model coefficients used to determine the Hazard
Score for each patient are shown on the forest plot (right). Patient survival at 24 months for the total
population sample is shown for the range of Hazard Scores (left), with the risk-groups delimited by vertical bars.
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Figure 3.12. Final model for Squamous Cell AJCC 3 Edition. Model coefficients used to determine the Hazard
Score for each patient are shown on the forest plot (right). Patient survival at 60 months for the total
population sample is shown for the range of Hazard Scores (left), with the risk-groups delimited by vertical bars.
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Figure 3.13. Final model for Squamous Cell AJCC 6 Edition. Model coefficients used to determine the Hazard
Score for each patient are shown on the forest plot (right). Patient survival at 24 months for the total
population sample is shown for the range of Hazard Scores (left), with the risk-groups delimited by vertical bars.
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Figure 3.14. Final model for Squamous Cell AJCC 7 Edition. Model coefficients used to determine the Hazard
Score for each patient are shown on the forest plot (right). Patient survival at 24 months for the total
population sample is shown for the range of Hazard Scores (left), with the risk-groups delimited by vertical bars.
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Figure 3.15. Sample output from the web-based version of the final model. Given the patient values submitted
by the user (left), the web-based model will estimate survival for each treatment category using the survival
observed for patients of a particular treatment modality and similar Hazard Score (right).

Discussion
It was shown that co-morbidities derived from administrative data contribute to a significant
improvement in prognostication. Specifically, the inclusion of a COPD variable was able to significantly
improve prognostication in several of the treatment groups considered as measured by metrics of
model fit and accuracy in controlled analyses and as an independent predictor. The presence of COPD
appears to have a strong effect on survival across the length of follow-up, with COPD patients having
significantly worse survival curves in four of the six groups considered. This was reflected in the
proportional test of COPD prevalence, where the group of patients with relatively shorter survival had a
significantly higher prevalence of COPD. Because a COPD designation was based on treatment of the
disease, the increased prevalence in patients with relatively shorter survival may reflect a higher degree
of COPD severity as a result of more severe cases having a higher likelihood of clinical diagnosis and
treatment. However, a quantitative determination of that effect is outside the scope of this analysis.
Additionally, splitting the patients further by the type of chemotherapy administered did not
reduce the prognostic ability of the covariate model previously described when compared to a model
using tumor stage alone(Putila et al., 2011), indicating that variable administration of chemotherapy
does not confound the benefit seen from the inclusion of other pathologic and demographic variables.
The relatively stronger effect of COPD in the squamous cell carcinoma patients in models controlling for
other variables may be indicative of the role of smoking on both survival and the presence of COPD
itself, given differences in the proportion of smokers between histologies (Papi et al., 2004; Kenfield et
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al., 2006; Bryant & Cerfolio, 2007), with squamous cell carcinomas being more closely associated with
smoking than adenocarcinomas.
Assessment of the effect of COPD is also important due to potential shared origins in the
development of the disease (Engels, 2008; Yao & Rahman, 2009; Houghton et al., 2008) and its role as a
potential confounder (Young et al., 2008) in prognostic models. It is hypothesized that inflammation
may initiate or promote tumorigenesis in the lung. This action is thought to center around the induction
of immune dysfunction and the destruction of the extra-cellular matrix. While it is difficult to
demonstrate quantitatively given the data available in this set, there was no evidence found which
would suggest that the trajectory or treatment of COPD after diagnosis will affect survival estimation in
lung cancer patients when using disease-specific survival. It is however necessary to examine the role of
COPD within treatment and stage sub-set, in order to account for known confounders such as treatment
candidacy and complication rate (Janssen-Heijnen et al., 1998; Rancati et al., 2003). After considering
the effects of COPD in influencing treatment selection, there is no compelling statistical reason to avoid
the use of a proportional hazards model or COPD status despite possible shared origins between COPD
and lung cancer in vivo. Conversely, other co-morbid conditions such as heart or cerebro-vascular
disease are more likely to derive their prognostic value from confounding or artifactual influences such
as socio-economic status or lifestyle differences, as there are only tenuous causal pathways for their
effects on disease-specific survival. Thus, their inclusion, while potentially beneficial from a statistical
standpoint, is imprudent when attempting to model factors directly influencing patient survival. For
these reasons, and as a matter of simplicity and generalizability, COPD alone was added to the previous
model in lieu of multiple conditions.
The SEER portion of the data is composed of a geographically and demographically diverse
group of patients by design and thus allows for a more accurate analysis of the effect of multiple
variables on survival. The large size and scope of the data also allow for assessing the accuracy of the
model across a wide range of treatments and patient profiles. This is especially relevant when studying
the effects of race or comorbidity, factors which have previously been shown to influence survival due
to differences in treatments administered (Bach et al., 1999). Given the assessment of disease-specific
survival stratified by treatment modality, it is highly likely that the effect of COPD represents an
additional source risk to the patient beyond that attributable to reduced candidacy, complication rate,
or reduced lung function after treatment. The model also accounts for recoding of cancer cases to the
newest version of the AJCC staging schema, where possible, and includes both major non-small cell
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histologies although the utility of COPD is less pronounced in the 6th Edition and recoded 7th Edition
samples. A possible explanation for this is that the newer patient groups have both a smaller samplesize and a shorter period of follow-up. It is possible that important manifestations of differences in
survival due to COPD may occur beyond the three-year mark or that more recent improvements in the
clinical management of COPD cases may alleviate some of the disparity in survival, but this was not
assessed.
A limitation of the data is that Medicare coverage is limited to those over the age of 65, with
some exceptions, and thus the age distribution of patients included is likely biased toward the upper
end of what would be seen in clinical practice. Additionally, the administration of chemotherapeutics or
other treatments not covered by Medicare is not recorded in the data, although Medicare covers a
significant portion of cancer care in patients who are eligible (Thorpe & Howard, 2003). As the
treatments administered to each patient were non-random, it is also difficult to accurately assess the
relative benefit of each type of treatment with a high degree of certainty and thus for this and other
reasons the results should not be interpreted as a measure of comparative treatment effectiveness. It
should also be noted that although administrative data is adequate for assessing co-morbidities and the
use of chemotherapeutics (Deyo et al., 1992; DHoore et al., 1996), these ascertainments may have
limited generalizability to more refined clinical or functional measures capturing the severity or
duration of disease. The absence of information on smoking status may also limit the model, as smoking
has been seen to influence survival independent of co-morbidities (Tammemagi et al., 2004). While the
metrics used to assess model performance indicate that the proposed model has a high degree of
internal validity, an external validation set was not used and thus caution must be exercised when
generalizing to other populations. Conversely, this type of prognostic model shows the greatest
individual-level improvement in survival when identifying high-risk patients who would otherwise have
been misclassified and treated as a lower-risk patient when using stage alone. In that regard, the
assessments used bias the results toward the null, as potential large improvements in a single patient
are averaged over the group.
Our results suggest that the addition of co-morbid conditions, specifically COPD, to a
comprehensive prognostic model improves prognostication over similar models without that
information. This represents an additional improvement over the use of stage alone, even in a
statistically rigorous manner, which was shown previously. Additionally, stratifying patients by the
administration of chemotherapeutic agents does not affect the performance of the model. The
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presence of COPD in patients may have an effect on survival independent of the effect attributable to
disparate treatment candidacy or quality of life. Thus, this approach and the resulting model have value
in identifying high-risk patients who may benefit from more aggressive therapies or enhanced follow-up.
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Chapter4:
Projection of prognostic and chemo-predictive microRNA
markers from a squamous cell lung cancer cohort to linked
SEER-Medicare data
Joseph Putila, Nancy Lan Guo

Abstract
Introduction: MiRNA are potentially important moderators of chemoresponse in human cancer due to
their widespread regulatory function. Identification of a set of clinically validated and biologically
relevant miRNA could serve as potential markers for prognosis, chemoresponse prediction, and novel
therapeutic targets. The objective of this study was to utilize population, clinical, and cell-line data as an
integrative approach to identifying miRNA showing a consistent association with chemoresponse.
Materials and Methods: Patients diagnosed with squamous cell carcinomas of the lung between 1991
and 2005 were retrieved from the linked SEER-Medicare database with data on tumor TNM markers,
grade, survival, and treatment information (N=33,897). Medicare HCPCS and Revenue codes were used
to identify patients receiving cisplatin (N=873), carboplatin (N=4,267), etoposide, (N=318), and paclitaxel
(N=3,098). The AJCC TNM markers and grade were used to partition patients into disjoint groups
indicative of tumor progression, with the average survival being calculated for each group. A second set
of clinical data containing miRNA expression (N=57, GSE 16025) was partitioned in the same manner,
with significant miRNA being selected by Cox and Kaplan-Meier modeling. Linear regression was used to
estimate the association between average miRNA expression in the clinical cohort and survival in the
population sample treated without chemotherapy across groups with similar tumor characteristics. The
same analysis was performed on the population set of patients receiving one of the four
chemotherapies, and compared to the results using the clinical cohort. A third analysis utilizing the NCI60 anti-cancer screen estimated the association between miRNA expression and drug activity in an
experimental setting. MiRNA which showed a significant association in the population set and
concordance in all others were considered for further analysis using IPA software.
Results: Multiple miRNA, including miR-433 and miR-520d* showed consistent associations with survival
across analytic approaches and treatments in the non-chemotherapy group. In patients treated with
chemotherapy, miR-199b and miR-142-3’ showed associations with chemoresponse in the clinical and
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cellular analyses. These and other significant miRNA formed networks which included experimentally
validated links with mediators of tumor growth, apoptosis, and cell-cycle control.

Introduction
Lung cancer is currently the leading cause of cancer-related death in the U.S., due in part to the
minimal response to chemotherapy and potential for recurrence (Hoffman et al., 2000; Naruke et al.,
1989; Vogt et al., 1999). Patients with similar clinical and pathological profiles may have markedly
different responses to a given treatment, indicating that classical markers of progression or tumor type
alone are not sufficient for the selection of an appropriate course of therapy. The use of biomarkers to
enhance treatment selection is a promising avenue for improving patient outcomes.
Numerous studies have shown that mRNA biomarkers can be used for predicting survival in lung
cancer patients (Wan et al., 2012; Raponi et al., 2006; Chen et al., 2007; Beer et al., 2002). Similar
studies have shown that miRNA can also be used in the diagnosis and prognosis of lung cancer (Wang et
al., 2009; Rabinowits et al., 2009; Yu et al., 2008; Markou et al., 2008; Fabbri et al., 2007; Raponi et al.,
2009). The development of a biomarker model of chemoresponse is particularly valuable due to the
high degree of chemoresistance in lung cancer (Vogt et al., 1999). Such a model has the potential to
both enhance response rates seen in patients treated with chemotherapy and to highlight the potential
regulatory networks which influence patient survival and mediate chemoresponse.
The variation in response to chemotherapy between patients is likely mediated, at least in part,
by micro-RNA (miRNA). These miRNA are short non-coding RNA sequences which have been shown to
be promising markers for both prognosis and response to therapeutics in multiple cancer types (Raponi
et al., 2009; Yan et al., 2011; Yu et al., 2008). There are a number of advantages to using miRNA such as
their presence in circulating plasma (Chen et al., 2012; Mitchell et al., 2008), and greater stability in
prepared tissue samples relative to mRNA (Jung et al., 2010; Mraz et al., 2009) including formalin
fixation (Xi et al., 2007). The use of miRNA markers in the selection of a biologically appropriate
treatment has the possibility of improving patient outcomes by determining the best application of
existing drugs, and the elucidation of pathways which may aid in the development of novel treatments
(Iorio & Croce, 2012; Avraham & Yarden, 2012).
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In selecting miRNA targets, many approaches have limited power to consider the effects of
surgical or radiological treatment due to sample size issues prompted by cost and recruitment barriers.
This problem is compounded by assignment to differing treatments based on traditional clinical
markers, confounding the use of survival time as an outcome. One potential solution is to utilize data
from larger clinical populations found in cancer registries to model the effects of miRNA expression on
patient outcomes in groups with similar surgical and radiological treatments. This approach allows for
the selection of miRNA markers which have promise for prognostication and prediction in a large and
diverse patient population. Similar approaches have had success identifying genes associated with
patient survival based on aggregate measures taken from population data (Stein et al., 2004).
Additionally, the approach more appropriately takes into account the effects of surgical and radiological
treatments in combination when assessing the role of miRNA in mediating chemoresponse as
represented by patient survival. Careful analysis of the known, experimentally validated biological
networks provides insight into the cellular processes which may be mediating this response, and several
interaction networks are presented as potential mediators of chemoresponse.

Materials and Methods
Patient cohorts
Two separate groups of patients were used in the analysis. The first is a cohort of 57 squamous
cell carcinoma patients originally published by Raponi et al. (Raponi et al., 2009). Included in this cohort
is expression data on 328 human miRNA determined by MirVana miRNA Bioarrays, with corresponding
follow-up information on survival time and status, tumor grade, and AJCC tumor T, N, and M markers.
Tumor grade for this cohort was converted from a descriptive measure of tumor differentiation to
numerical grade to match descriptors used in the second set.
The second patient group was derived from the linked SEER-Medicare (SM) database (Warren et
al., 2002b). This database combines the clinical, demographic, pathological, and survival information
from the NCI SEER registry system with claims data for individual patients found in the Medicare claims
database. Briefly, patients in the SEER portion were linked according to identifying information such as
social security number, census tract, age, and other identifying criteria to records found in the Medicare
claims database (Potosky et al., 1993). Criteria for inclusion in this study were a diagnosis of squamous
cell carcinoma of the lung or bronchus between 1991 and 2005, as well as valid information on survival
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time and status, tumor grade, and AJCC T, N, and M markers. A total of 33,897 patients fit these criteria,
with this sample being stratified according to treatment modality in subsequent analyses. Patient
demographics for this group are detailed in Table 4.1. The T, N, and M markers for patients diagnosed
prior to 2004 were derived from EOD10 coding, where possible, and according to established conversion
algorithms (Seiffert, 1993). Four specific chemotherapeutic agents, cisplatin, carboplatin, paclitaxel, and
etoposide were considered. The administration of chemotherapy was determined through the use of
Healthcare Common Procedure Coding System (HCPCS) codes (Warren et al., 2002a). First, the use of
chemotherapy was determined by searching individual patient claims histories for entries with an HCPCS
code corresponding to the agent in question. The ICD-9 diagnosis codes for these records were then
checked to ensure that the agent was administered for the treatment of lung cancer. Curative surgery
and radiation therapy were determined using variables in the SEER portion of the data. These variables
were used to stratify patients into a group receiving any surgical procedure but not pre-operative
radiation, a group with any type of radiation but not surgery, a group with both surgery and radiation,
and lastly a group with any combination of treatments. Survival estimates are represented as diseasespecific survival for the SM cohort and overall for the clinical cohort.
Table 4.1. Summary of demographic and clinical variables for patients in the linked SEER-Medicare and Clinical
cohorts.

Variable
Cancer Stage
Stage I
Stage II
Stage III
Stage IV
Unstaged/Other
Tumor Grade
Grade 1
Grade 2
Grade 3
Grade 4
Mean Age (σ)
Sex
Male
Female

SEER-Medicare Patients

Clinical Cohort (Raponi et al)

12,651 (37.3%)
2,662 (7.8%)
11,514 (34%)
5,813 (17.1%)
1,257 (3.7%)

34 (59.6%)
11 (19.3%)
12 (21.1%)
0 (0.0%)
0 (0.0%)

1,462 (4.3%)
13,573 (40.0%)
18,202 (53.7%)
660 (1.9%)
71.1 (7.9)

1 (1.8%)
28 (49.1%)
28 (49.1%)
0 (0.0%)
66.8 (10.7)

22,218 (65.5%)
11,679 (34.5%)

39 (68.4%)
18 (31.6%)
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Cellular Data
The cellular data against which the predictive markers are checked was derived from the NCI-60
cell panel (Shoemaker, 2006; Gaur et al., 2007) and contains miRNA expression levels of 209 miRNA
markers determined by quantitative-PCR across 59 cancer-derived cell lines of diverse tissue origin. The
data also contain the drug activity at three clinically relevant end-points: 50% Growth Inhibition (GI50),
Total Growth Inhibition (TGI), and 50% Lethal Concentration (LC50), used here to refine the set of
significant miRNA and assess meaningful biological context.
Identification of prognostic miRNA using a clinical cohort
Patients in the Raponi and SEER-Medicare sets were assigned to disjoint tumor progression
groups according to unique combinations of tumor grade and T, N, and M markers. This tumor
progression group membership served as a link between the two patient sets in subsequent analyses. In
total, there were 16 groups common between the clinical and population data sets, including tumor
grades 1 through 3, tumor T 1 through 4, and tumor N 0 through 2. There were no metastatic or grade 4
groups common between the two sets. A Leverage analysis was performed to test for undue influence
from any one group. None of the groups were seen to have a disproportionate effect on model
coefficients or significance; therefore all 16 groups were included.
The set of prognostic miRNA was determined by selecting miRNA which showed a significant
association with survival in the original clinical cohort, then validating these miRNA in the population
cohort. Cox modeling and Kaplan-Meier estimation were used to assess the association between
expression and survival in the original clinical cohort. Cox model coefficients and p-values were
estimated for each miRNA in independent models. In the Kaplan-Meier analysis, cutoff values ranging
from the 5% to 95% quantile were used to split the patients into high and low survival groups. The
degree of separation between the resulting survival curves was estimated as a log-rank p-value, with a
value less than 0.05 being deemed as significant separation between the groups.
Validation of prognostic miRNA markers using linked SEER-Medicare data
Validation of the results of the clinical analysis on the population data was done using linear
regression, Cox modeling, and Kaplan-Meier estimation. Multiple methods of assessment were chosen
due to limitations associated with using a single measure (Pepe et al., 2004). The linear regressions used
the average miRNA expression from the clinical set and average disease-specific survival from the
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population set for each tumor progression group. Average survival in the population cohort was
calculated as a function of the area under the curve produced by Kaplan-Meier estimation. Each miRNA
was evaluated in each of the four surgical and radiological treatment modalities. In order to enter the
final set of prognostic miRNA, each miRNA found to be significant in the original cohort had to show a
concordant and significant association with average survival in the population cohort. Individual
patients in the population cohort were then assigned the average miRNA expression for that progression
group from the clinical cohort and the Cox and Kaplan-Meier models were re-evaluated. Any miRNA
which failed to achieve a significant and concordant association with survival in one of either the Cox or
Kaplan-Meier models were removed.
Identification of predictive miRNA using linked SEER-Medicare data
In order to select for miRNA which were predictive of chemoresponse, as represented by
improved or diminished disease-specific survival, linear regression was again used to estimate the
association between average miRNA expression in the clinical cohort and disease-specific survival in the
population cohort by tumor progression group. Next, each patient in the population set was assigned
the average expression for each miRNA corresponding to the same tumor progression group in the
clinical cohort. This combined set of patient expression and survival data was then used to estimate a
Cox proportional hazards model. A Kaplan-Meier model was also estimated and assessed on the logrank P-values. Significance and concordance on the linear model and one of either the Cox or KaplanMeier models was sufficient evidence in the population analysis. Selection of a particular miRNA as a
prognostic marker was not a requirement for selection as a predictive marker.
Validation of predictive miRNA using the NCI-60 anti-cancer screen
The miRNA which were significant in the predictive analyses were then compared to data from
the NCI-60 anti-cancer screen (Boyd & Pauli, 1995; Gaur et al., 2007; Weinstein, 2006). Linear regression
was used to estimate the association between expression on a specific miRNA marker in each cell line
and drug activity in the same cell line for each of the previously described end-points. Cell-lines which
did not have informative values, specifically those which did not achieve the end-point in question at
any dosage, were removed from the analysis. Significance and concordance on any one of the three
drug activity measures was considered support of meaningful biological context, and these miRNA
formed the final of predictive set.
Evaluating Predictive miRNA using Pathways Analysis
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For each agent, the final set of significant miRNA were also examined for interactions with
molecular species known to play a role in lung cancer or relevant cellular processes such as apoptosis,
proliferation, cell-cycle regulation, or metastasis through the use of Ingenuity Pathways Analysis (IPA)
(Ingenuity® Systems, www.ingenuity.com). In short, IPA is a functional pathway analysis tool
incorporating genes, cellular species such as proteins, and chemical compounds with data on their
interactions and involvement in diseases derived from scholarly publications. Using this data, it is
possible to map interactions between biomarkers on any given criterion. The list of significant miRNA
from each treatment was used to create networks based on experimentally validated interactions
between miRNA and molecular components with known biological function. These networks were
created using the Core Analysis feature of IPA, and can be seen in Figures 4.5 through 4.8. The Core
Analysis compares the set of miRNA markers with molecules with known roles in human disease in order
to select a set of networks in which the interactions between the miRNA set and IPA-defined functional
set are statistically over-represented.

Results
Prognostic miRNA
Prognostic analyses were performed in the group of patients without indication of having
received chemotherapy. In patients treated with surgery and without chemotherapy miR-520d*, miR433, miR-134, and miR-382 were positively and three others were negatively associated with survival. In
the sub-set of patients receiving radiation without surgery or chemotherapy, a single miRNA, miR-433
was positively associated with survival. In patients receiving both surgery and radiation without
chemotherapy, there were 3 positive and 1 negative associations, with miR-520d* again being positively
associated with survival. For patients receiving any surgical or radiation treatment without
chemotherapy, 9 miRNA including miR-520d* and miR-433 were positively associated, with miR-384 and
two others negatively associated with survival. The specific miRNA and their relationship with diseasespecific survival are outlined in Table 4.2. Multiple miRNA were significant across surgical and radiation
modalities. Two miRNA, miR-433 and miR-520d*, were positively associated in multiple treatment
combinations considered, indicating a strong but non-specific effect on survival. The results of the
analyses on miR-433 and miR-520d* are detailed in Figures 4.1 and 4.2, respectively.
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Table 4.2. Total number of significant miRNA when considering variable administration of surgery,
chemotherapy, and radiation in the SEER-Medicare and clinical cohort.

Treatment
Surgery
Radiation
Surgery and
Radiation
Any
Treatment

No Chemotherapy
Positive Correlation
Negative Correlation
miR-520d*, miR-433,
miR-328, miR-384,
miR-134, miR-382
miR-525*
miR-433
miR-453, miR-520d*,
miR-197
miR-134
miR-453, miR-372,
miR-142-3’, miR-329,
miR-328, miR-197,
miR-520d*, miR-433,
miR-384
miR-134, miR-382,
miR-493-3’
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Figure 4.1. Relationship between expression of miR-433 and survival in patients from the population set treated
without chemotherapy, and the original clinical cohort. Treatment groups shown are surgery without
chemotherapy (top left), radiation without chemotherapy (top right), any treatment without chemotherapy
(bottom left), and the clinical cohort regardless of treatment (bottom right).
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Figure 4.2. Relationship between expression of miR-520d* and survival in patients from the population set
treated without chemotherapy, and the original clinical cohort. Treatment groups shown are surgery without
chemotherapy (top left), both surgery and radiation without chemotherapy (top right), any treatment without
chemotherapy (bottom left), and the clinical cohort regardless of treatment (bottom right).
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Predictive miRNA
In addition to those found to be prognostic, numerous miRNA were found to predictive of
survival when patients treated with any chemotherapy or a specific agent were considered independent
of those patients not receiving chemotherapy. The results of these analyses are summarized in Tables
4.3 and 4.4, with the significant sets being split into chemo-sensitive and chemo-resistant for
presentation.
Cisplatin
In patients who received surgery with cisplatin, 9 miRNA were negatively associated, with one miRNA
positively associated. Two of the negatively associated miRNA in that group, miR-181b and miR-181c
have highly similar mature sequences. For patients receiving radiation with cisplatin a single miRNA,
miR-384, was negatively associated. In patients receiving both surgery and radiation there were no
significant associations in the cisplatin group. For those receiving cisplatin in combination with any
surgical or radiation treatment there were 8 positive and 8 negative associations.
Carboplatin
When patients receiving surgery with carboplatin were considered miR-134, miR-142-3’, and
two others were positively associated. An additional 4 were negatively associated. In patients receiving
radiation with carboplatin there were not any significant associations. In patients receiving both surgery
and radiation miR-134 and miR-142-3’were positively associated and 2 others negatively associated.
When patients receiving carboplatin in combination with any treatment were considered, a total of 6
miRNA were positively associated with survival, with a further 4 miRNA being negatively associated.
Tables 4.3 and 4.4 detail the identities of the significant miRNA by treatment modality.
Paclitaxel
In patients receiving paclitaxel with surgery there were 5 miRNA positively and 7 negatively
associated with survival. Two miRNA, miR-154 and miR-302a*, were positively associated with survival
in patients receiving radiation with paclitaxel with one negative association. In patients who received
both surgery and radiation miR-142-3’ and miR-220 were positively associated with 5 others negatively
so. In patients receiving paclitaxel in combination with any other treatment there were 5 miRNA
positively associated and 6 miRNA negatively associated with survival. Both miR-142-3’ and miR-199b
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were also significant in the clinical and cellular analyses, the results of which are outlined in Figures 4.3
and 4.4, respectively.
Etoposide
For patients receiving etoposide in combination with any treatment, 9 miRNA were positively
and 9 negatively associated with survival. There were no miRNA significantly associated with survival in
patients receiving only surgery. A single miRNA, miR-223 was negatively associated with survival in
patients receiving both surgery and radiation. For patients receiving radiation with etoposide, there
were 9 positive and 5 negative associations.
Non-specific Chemotherapy
The last group considered consisted of patients with an indication of having received any
chemotherapy, including any of the four previously listed. Patients in this group having received surgery
with chemotherapy had 2 positive and 2 negative associations, including miR-142-3’ being positively
associated as was the case for the specific treatment groups. In the radiation group there was 1 positive
and 1 negative association. In the group receiving both surgery and radiation there was 1 positive
association, miR-142-3’, along with 2 negative associations. When any treatment with chemotherapy
was considered, there were 14 positive associations, including both miR-520d* and miR-433, and 7
negative associations.
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Figure 4.3. Relationship between expression of miR-142-3’ and survival in the population analysis, and
expression and LC50 in the cellular panel when treated with paclitaxel. Average expression of miR-142-3’
showed a positive correlation with survival in the population analysis (A), which was corroborated in the cellular
panel by a decrease in the dosage required for LC50 (B). This effect was also apparent when stratifying the
groups based on expression level in all patients treated with paclitaxel (C), and persisted when only the surgical
group was considered (D).
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Figure 4.4. Relationship between expression of miR-199b and survival in the population analysis, and expression
and LC50 in the cellular panel when treated with paclitaxel. Average expression of miR-199b showed a positive
correlation with survival in the population analysis (A), which was corroborated in the cellular panel by a
decrease in the dosage required for LC50 (B). This effect was also apparent when stratifying the groups based
on expression level in all patients treated with paclitaxel (C), and persisted when only the surgical group was
considered (D).
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Table 4.3. Total number chemosensitive miRNA when considering administration of specific chemotherapeutic
agents in combination with variable administration of surgery and radiation, as evidenced by prolonged diseasespecific survival. The miRNA which produced a significant stratification in the SEER population samples in
addition to significance on one or more measures of drug activity in the NCI-60 panel are bolded.

Treatment

Surgery

Cisplatin

Carboplatin

miR-29b

miR-134,
miR-142-3’,
miR-188,
miR-380-5’

Paclitaxel
miR-134,
miR-138,
miR-142-3’,
miR-188,
miR-380-5’

Etoposide

Any Chemo

-

miR-142-3’,
miR-433

miR-134

Radiation

-

-

miR-154,
miR-302a*

Surgery
and
Radiation

miR-141,
miR-17-3’,
miR-17-5’,
miR-182,
miR-183,
miR-19b,
miR-200c,
miR-222,
miR-23b

-

miR-134,
miR-142-3’

miR-142-3’,
miR-220

-

miR-142-3’

Any
Treatment

miR-129,
miR-134,
miR-142-3’,
miR-184,
miR-198,
miR-370,
miR-373,
miR-379

miR-134,
miR-142-3’,
miR-199b,
miR-370,
miR-382

miR-129,
miR-141,
miR-142-3’,
miR-184,
miR-218,
miR-220,
miR-335,
miR-373,
miR-96

miR-33, miR-453,
miR-372, miR-142-3’,
mir-299-3’, miR-329,
miR-520d*, miR-519a,
miR-494, miR-433,
miR-134, miR-485-5’,
miR-518c*, miR-493-3’

miR-134,
miR-142-3’,
miR-206,
miR-33,
miR-370,
miR-372
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Table 4.4. Total number chemoresistant miRNA when considering administration of specific chemotherapeutic
agents in combination with variable administration of surgery and radiation, as evidenced by shortened diseasespecific survival. The miRNA which produced a significant stratification in the SEER population samples in
addition to significance on one or more measures of drug activity in the NCI-60 panel are bolded.

Treatment

Surgery

Radiation

Cisplatin
miR-126*,
miR-136,
miR-181b,
miR-181c,
miR-196a,
miR-331,
miR-375,
miR-424,
miR-92

Carboplatin

Paclitaxel

Etoposide

Any Chemo

miR-126,
miR-192,
miR-195,
miR-384

miR-189,
miR-192,
miR-197,
miR-301,
miR-328,
miR-331,
miR-384

-

miR-197,
miR-384

miR-384

-

miR-189

miR-328

miR-192,
miR-384

miR-192,
miR-197,
miR-328,
miR-331,
miR-384

miR-150,
miR-155,
miR-192,
miR-337,
miR-98
miR-223

miR-328,
miR-197,
miR-384

miR-132,
miR-133b,
miR-155,
miR-197,
miR-208,
miR-214,
miR-324-3’,
miR-374,
miR-423

miR-328,
miR-361,
miR-511,
miR-197,
miR-125a,
miR-384,
miR-126

Surgery
and
Radiation

-

Any
Treatment

miR-132,
miR-181b,
miR-30c,
miR-30e-3’,
miR-324-3’,
miR-331,
miR-339,
miR-384

miR-126,
miR-195,
miR-224,
miR-384

miR-126,
miR-224,
miR-328,
miR-331,
miR-361,
miR-384
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Discussion
These results demonstrate that, based on similarities in tumor progression, extrapolation of
miRNA expression from smaller cohorts to larger population-based data can serve both as an additional
confirmatory tool where novel cohorts are unavailable and as an independent source of prognostic and
predictive markers. Specifically, it was shown that multiple miRNA were selected as strong predictors of
chemoresponse though analysis of disease specific survival in cohorts with similar treatment strategies.
The miRNA selected for also have a strong biological context relative to cellular processes important to
cancer progression and patient survival such as apoptosis, suggesting that they play a role in mediating
the effectiveness of chemotherapeutic agents through their regulatory function.
In patients treated with paclitaxel, miR-199b was positively associated with survival, an effect
which may be indicative of a number of potential regulatory actions. In particular, miRNA-199b may
decrease translation of LAMC2, a key growth factor for non-small cell lung cancer, and may confer a
protective effect due to a reduction in metastatic potential (Manda et al., 2000) and loss of protection
against anoikis (Kodama et al., 2005). The same miRNA also increases inhibition of PAK4, a protein
kinase suspected of promoting tumor survival, proliferation, and metastasis in a variety of cancers (Mak
et al., 2011; Liu et al., 2008). Similarly, miR-29b was seen to be protective and may also reduce
metastatic potential by acting as a DNMT inhibitor and reverting aberrant methylation patterns (Chang
et al., 2006; Fabbri et al., 2007). The miRNA in the significant sets also had known associations with one
or more functional networks pertinent to chemoresponse. Additionally, cancer was the top disease for
three of four specific chemotherapy groups considered based on the degree of overlap between the
significant miRNA and molecules identified in IPA as being related to cancer. A summary of these
networks is provided in Tables 4.5 through 4.7. The networks resulting from the Core Analysis
performed in IPA are shown in Figures 4.5 through 4.8.
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Table 4.5. Networks derived from a Core Analysis performed in Ingenuity Pathway Analysis. The corresponding
networks are detailed in Figures 4.5 through 4.8. Focus molecules represent miRNA from the original set which
demonstrated a high degree of interconnectivity, and were subsequently used to establish the network score. A
significant p-value indicates a low probability of the miRNA set being selected at random.

Treatment Group
Cisplatin
Carboplatin
Paclitaxel
Etoposide

Network ID
Connective Tissue Disorders, Inflammatory Disease,
Inflammatory Response
Connective Tissue Disorders, Inflammatory Disease,
Inflammatory Response
Genetic Disorder, Skeletal and Muscular Disorders,
Developmental Disorder
Respiratory Disease, Inflammatory Response,
Connective Tissue Disorders

Focus Molecules
14

p-value
<0.0001

11

<0.0001

17

<0.0001

14

<0.0001

Table 4.6. Top Diseases and Disorders derived from a Core Analysis performed in Ingenuity Pathway Analysis.
The corresponding diseases or disorders were selected based on the degree of overlap between the miRNA
selected in that treatment group and those defined in the IPA database as being associated with that disease
beyond random chance (p<0.05). These results, unlike those represented in Table 4.5, do not factor the degree
of connectivity.

Treatment Group
Cisplatin
Carboplatin
Paclitaxel
Etoposide

Disease or Disorder
Cancer
Cancer
Cancer
Inflammatory Response

# Molecules
34
20
26
24

Table 4.7. Top Molecular and Cellular functions derived from a Core Analysis performed in Ingenuity Pathway
Analysis. The corresponding functions were selected based on the degree of overlap between the miRNA
selected in that treatment group and those defined in the IPA database as being associated with that function
beyond random chance (p<0.05). These results, unlike those represented in Table 4.5, do not factor the degree
of connectivity.

Treatment Group
Cisplatin
Carboplatin
Paclitaxel
Etoposide

Function
Cell Death
Cell Cycle
Cellular Growth and Proliferation
Cellular Development

# Molecules
9
3
10
26
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Figure 4.5. Overview of network derived from IPA Core analysis, representing interactions between miRNA
found to be chemopredictive for cisplatin and species relevant to the significant functions and diseases listed in
Table 4.5. Canonical Pathways (CP:) and Functions and Diseases (Fx:) as defined by IPA are overlaid to highlight
the interconnectedness of the set with molecular processes relevant to chemoresponse. Predictive miRNA
whose expression was positively associated with survival are shown in green, and those who expression was
negatively associated are shown in red.
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Figure 4.6. Overview of network derived from IPA Core analysis, representing interactions between miRNA
found to be chemopredictive for carboplatin and species relevant to the significant functions and diseases listed
in Table 4.5. Canonical Pathways (CP:) and Functions and Diseases (Fx:) as defined by IPA are overlaid to
highlight the interconnectedness of the set with molecular processes relevant to chemoresponse. Predictive
miRNA whose expression was positively associated with survival are shown in green, and those who expression
was negatively associated are shown in red.
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Figure 4.7. Overview of network derived from IPA Core analysis, representing interactions between miRNA
found to be chemopredictive for paclitaxel and species relevant to the significant functions and diseases listed in
Table 4.5. Canonical Pathways (CP:) and Functions and Diseases (Fx:) as defined by IPA are overlaid to highlight
the interconnectedness of the set with molecular processes relevant to chemoresponse. Predictive miRNA
whose expression was positively associated with survival are shown in green, and those who expression was
negatively associated are shown in red.
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Figure 4.8. Overview of network derived from IPA Core analysis, representing interactions between miRNA
found to be chemopredictive for etoposide and species relevant to the significant functions and diseases listed
in Table 4.5. Canonical Pathways (CP:) and Functions and Diseases (Fx:) as defined by IPA are overlaid to
highlight the interconnectedness of the set with molecular processes relevant to chemoresponse. Predictive
miRNA whose expression was positively associated with survival are shown in green, and those who expression
was negatively associated are shown in red.
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In most cases miRNA had a similar association with survival across the surgery and radiation
treatment groups, although some miRNA gained or lost significance depending upon the treatment.
This may be due to moderation of the effect by treatment type, but is likely due at least in part to
differing sample sizes between treatment modalities. In general, miRNA with highly similar sequences
had a similar association with survival, even if one or more of the similar miRNA failed to achieve
significance in a given analysis, i.e. the miR-181b/c group and the 3’ and 5’ strands of miR-17. This may
indicate that targets shared by these miRNA may be more central to the observed mediation than those
affected by only a single miRNA. Additionally, many of the results from the IPA analyses indicate that
these sets of miRNA, and their corresponding networks, play a role in apoptosis, cellular growth, and
proliferation. All four of the significant sets from the analyses on individual agents had aspects of
cellular growth or death as their top biological function. In addition, an overlay of canonical pathways
and cellular functions shows that many of the networked molecules derived from the same sets are also
related to apoptosis or cell-cycle regulation (Figures 4.5 to 4.8). This suggests that the significant miRNA
may act in a broad pattern of expression to modulate the response of tumor cells to chemotherapeutic
agents, as indicated by improved or diminished survival by patients treated with those agents.
There are however multiple limitations to this approach. The first is the assumption that miRNA
expression patterns in patients in the Raponi cohort are representative of those in other patients with
similar disease status. The accuracy to which these expression patterns can be estimated is also limited
by the smaller sample size. Adequate sample size is a problem inherent to similar studies to date. In
addition, the Raponi cohort lacks patients with stage 4 tumors. Although the benefit of chemotherapy
in Stage 4 cases is better characterized than in earlier stages, the absence of stage 4 data for our method
nonetheless affects the generalizability of the results.
The use of administrative data also has some important implications. Although the SEER data
are in general highly accurate, it is not fully inclusive of all treatments a patient may receive.
Treatments not covered by Medicare or covered by other forms of insurance would not appear in the
database. Additionally, eligibility requirements for Medicare coverage artificially limit the patient
sample to those over the age of 65, with notable exceptions such as eligibility due to disability benefits.
However, as lung cancer occurs primarily in older populations the effect is limited relative to other
cancer types which are common in comparatively younger populations.
By design, the SEER registry represents a more demographically and clinically diverse group of
patients when compared to cohorts limited to a specific geographic area or healthcare system. Finally, it
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should be noted that many of the miRNA found to be predictive or prognostic lacked any significant
annotation which would allow for their potential biological roles to be ascertained, so the exclusion of a
particular miRNA does not necessarily indicate a null effect.
Despite these limitations, this approach allowed for the identification of miRNA which were
useful for both prognostication and prediction of response to chemotherapy through consideration of
both clinical and population-based measures of survival, in addition to cellular response and biological
context. Stratification of the analyses on treatment modality mitigates the effect of differential
treatment assignment on the length of survival. This allows for ascertainment of the contribution of
miRNA markers to survival and chemoresponse independent of treatment effects. Further refinement
and validation of this approach holds the potential for identification of miRNA regulatory pathways
which may mediate chemoresponse and survival in a large number of patients.
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Chapter 5:
Conclusion
Two unresolved issues in the treatment of lung cancer, assessment of risk of recurrence and the
selection of an effective chemotherapeutic agent for patients with similar tumor morphology, were
identified as potential areas for the application of prognostic and predictive models of patient survival.
It was shown that given an appropriate theoretical framework, each of the major unresolved issues can
be approached through the use of comprehensive prognostic and predictive models incorporating
demographic, clinical, and biomarker information.
The second chapter developed an analytical framework for using registry information to develop
a prognostic model for lung cancer patients. Information on tumor stage, grade, patient age, race, and
sex was used to construct a comprehensive model of patient survival which was shown to be superior to
a similar model using tumor stage alone. The model which was developed offered measurable
improvements in prognostication across a wide variety of patients and was able to be translated into an
intuitive tool suitable for use in clinical practice. It was shown that reliable information on tumor
morphology, demographic information, and follow-up can be derived for a larger set of patients than
would be feasible to enroll in a prospective study. The larger patient sample allowed for a more robust
assessment of internal validity and assessment within treatment modality. The analytical framework
established in Chapter 2 also served as a basis for further extending the comprehensive prognostic
model in the third chapter.
The third chapter expanded the prognostic ability of the previously defined model by assessing
the role of co-morbidity in affecting disease-specific survival and the effect of chemotherapy on
prognostication. It was found that a variety of co-morbid conditions can affect survival. Of these, COPD
was chosen due to its strong independent effect on survival, improvements in prognostication in a
comprehensive model, and persistence of these effects within treatment sub-groups. The results show
that COPD has a dual effect both as a confounder for treatment candidacy and as a driver of both long
and short-term patient survival. Because of this, COPD was chosen to be added to the previously
defined model. Through the use of linked Medicare data, it was also possible to assess the effect of
COPD status on survival and the prognostic ability of the previously defined comprehensive model in
groups of patients receiving chemotherapy.
The web-based application of the models developed in Chapters 2 and 3 demonstrated how the
comprehensive prognostic model can be translated into a useful and intuitive tool for clinicians. The
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comprehensive model of patient survival presented In Chapters 2 and 3 incorporated multiple
demographic and clinicopathologic variables to create a single measure of patient risk, a Hazard Score,
used in estimating expected survival at various timepoints. This single Hazard Score was also used to
estimate survival relative to other patients, and as a factor for the selection of high-and low-risk patients
assesed using the web-based prognostic model.
The fourth chapter demonstrated that the projection of miRNA expression onto a population
cohort from a comparatively smaller group of patients can be a useful approach to validating and
selecting miRNA indicative of influencing chemoresponse and prognosis. The large, well-annotated, and
diverse population of patients in the linked SEER-Medicare database served as a secondary source of
patient survival data. By linking the clinical and population cohorts through the use of shared tumor
progression categories it was possible to select a set of miRNA which showed a strong association with
survival in patients receiving a variety of chemotherapeutic, surgical, and radiological treatments. These
miRNA sets were then further validated using cell-line data, resulting in a set of miRNA which exhibited
strong interconnectivity with molecules known to play a role in processes pertinent to response to a
chemotherapeutic agent.
Future analyses using this framework would benefit from the refinement of COPD and
treatment variables. Examining the role of COPD in biasing the type of surgery performed, i.e. lobe or
wedge resection, and the effect of COPD after receiving each of these treatments will give better insight
into how the disease influences survival due to treatment candidacy and as a prognostic factor.
Similarly, the specific type of radiation administered and the associated outcomes may also be
influenced by COPD. New procedures such as Stereotactic Radioablation or Cyber-Knife offer improved
outcomes over traditional radiotherapy (Brown et al., 2007a; Brown et al., 2007b), and may greatly
benefit patients whose tumor may be inoperable due to COPD. It may also be possible to gauge the
severity of COPD in patients identified as having the condition. One proposed method would use
oxygen dependence status to split COPD patients into two groups; an oxygen dependent group with
presumably more advanced disease, and another group not dependent on oxygen with presumably less
advanced disease. This refinement in COPD status paired with determining the specific type of surgery
and radiation received may help to further elucidate the role of COPD in influencing treatment
candidacy and survival.
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